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Abstract 
Elevated concentrations of albumin in the urine, albuminuria, are a hallmark of diabetic kidney 
disease and associate with increased risk for end-stage renal disease and cardiovascular events. 
To gain insight into the pathophysiological mechanisms underlying albuminuria, we conducted 
meta-analyses of genome-wide association studies and independent replication in up to 5,825 
individuals of European ancestry with diabetes mellitus and up to 46,061 without diabetes, 
followed by functional studies. Known associations of variants in CUBN, encoding cubilin, with 
the urinary albumin-to-creatinine ratio (UACR) were confirmed in the overall sample (p=2.4*10
-
10
). Gene-by-diabetes interactions were detected and confirmed for variants in HS6ST1 and near 
RAB38/CTSC. SNPs at these loci demonstrated a genetic effect on UACR in individuals with but 
not without diabetes. The change in average UACR per minor allele was 21% for HS6ST1 and 
13% for RAB38/CTSC (p=6.3*10
-7
 and 5.8*10
-7
, respectively). Experiments using streptozotocin-
treated diabetic Rab38 knockout and control rats showed higher urinary albumin 
concentrations and reduced amounts of megalin and cubilin at the proximal tubule cell surface 
in Rab38 knockout vs. control rats. Relative expression of RAB38 was higher in tubuli of patients 
with diabetic kidney disease compared to controls. The loci identified here confirm known and 
highlight novel pathways influencing albuminuria. 
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Introduction 
Urinary albumin and serum creatinine are two biomarkers recommended for routine 
assessment of chronic kidney disease (CKD).(1) Even at physiological rates of glomerular 
filtration, small elevations in urinary albumin concentrations are associated with an increased 
risk for CKD progression, end-stage renal disease (ESRD), cardiovascular events and both 
cardiovascular and all-cause mortality.(2–4) Patients with diabetes mellitus are at particularly 
high-risk for CKD and its sequelae: the prevalence of CKD among individuals with diabetes is 
>40% compared to about 10% in the general U.S. adult population,(5) and the presence of CKD 
is an important contributor to the excess mortality in diabetes.(6) The appearance of significant 
amounts of albumin in the urine (albuminuria) is a hallmark of diabetic kidney disease (DKD), 
the incidence of which continues to rise along with type 2 diabetes worldwide.(7) Even in 
treated individuals, residual diabetes-related microvascular risk represents an important 
challenge,(8) and DKD remains the leading cause of ESRD. No new effective treatments for DKD 
have been approved in more than two decades,(9) highlighting the importance to better 
understand its underlying mechanisms.  
Using genome-wide association study (GWAS) meta-analysis in general population 
cohorts, we previously identified a missense single nucleotide polymorphism (SNP) in the gene 
encoding cubilin (CUBN) in association with the urinary albumin-to-creatinine ratio (UACR).(10) 
CUBN is currently the only genome-wide significant locus for UACR. However, this variant 
explains only a small fraction of the previously reported heritability of albuminuria ranging from 
0.2-0.46 in the general population and those with diabetes,(11–13) suggesting that additional 
genetic variants remain to be found. Here we report the results of a GWAS meta-analysis of 
albuminuria traits in the general population performed in almost twice the sample size of our 
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previous study,(10) with a special focus on those with diabetes, replication in additional 
independent individuals, and follow-up investigations in human tissues and a genetically 
modified animal model of diabetes mellitus. 
 
Research Design and Methods 
Study Populations 
Our study was based on 30 discovery and replication studies mostly from the general 
population, with the exception of ADVANCE and GENDIAN that enrolled exclusively individuals 
with type 2 diabetes, totaling 67,452 participants of European ancestry across the different 
analyses (up to 7,787 with diabetes in discovery and replication). The study characteristics, 
including the distribution of albuminuria and diabetes, are shown in Supplementary Table 1. 
Study protocols were approved by each local Institutional Review Board or Ethics Committee, 
and all human participants gave written informed consent. 
  
Phenotype Definitions and Analytical Strategy 
The measurement of urinary albumin and creatinine in each study is reported in Supplementary 
Table 2. Urinary albumin values below the detection limit of the used assays were set to the 
lower limit of detection. Rather than using urinary albumin, the urinary albumin-to-creatinine 
ratio (UACR) was calculated as urinary albumin/urinary creatinine (mg/g) to account for 
differences in urine concentration. Microalbuminuria (MA) was defined as UACR >25 mg/g in 
women and >17 mg/g in men.(10) Diabetes was defined as fasting glucose ≥126 mg/dl, non-
fasting glucose ≥200 mg/dl or treatment for diabetes, or – if this information was not available - 
based on self-report. Across studies, we evaluated two traits, UACR and MA, and performed 
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four GWAS meta-analyses: MA and UACR in the overall sample, as well as UACR – a continuous 
trait with higher statistical power - separately among those with and without diabetes. 
Diabetes-stratified genome-wide association analyses of MA were not performed due to limited 
sample size. Detailed information on each study’s design, genotyping, imputation and data 
management is provided in Supplementary Tables 2 and 3. 
 
Discovery Meta-Analysis, Replication and Power 
Stringent quality control of the genetic data was performed at the individual study level and 
again at the meta-analysis level using state-of-the-art methods. Missing genotypes were 
imputed using the HapMap reference panels in 19 studies and the 1000 Genomes reference 
panels in two studies. Details of genotyping, imputation software, reference panels, and quality 
filters in each study are reported in Supplementary Table 3. 
All studies performed GWAS following a standardized analysis protocol. In each study, the 
natural logarithm of UACR was taken. Subsequently, sex-specific residuals were obtained from 
linear regression models of ln(UACR) on age and study-specific covariates, including study 
center and genetic principal components to adjust for possible population stratification if 
applicable. The continuous sex-specific residuals were then combined and used as the 
dependent variable that was regressed on imputed allelic dosages for each SNP in the GWAS.  
Prior to meta-analyses, all study-specific GWAS summary files underwent quality control 
using GWAtoolbox.(14) Genomic-control (GC)(15) correction was applied when the GC factor 
was >1. Inverse-variance weighted fixed-effects meta-analyses were then conducted using 
METAL.(16) The I
2
 statistic was used to evaluate between-study heterogeneity.(17) All meta-
analyses were carried out in duplicate by two independent researchers. 
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After meta-analysis, SNPs with average minor allele frequency (MAF) <0.01 were 
excluded, and another GC correction was applied. There were 2,191,945 SNPs with average 
MAF >0.05 and present in >50% of the studies, which were then clustered based on correlation 
(linkage disequilibrium pruning using r
2
≤0.2) with the respective index SNP (the SNP with the 
lowest p-value) within windows of ±1 MB to identify independent SNPs with suggestive 
association (p<10
-5
) in one or more of the four analyses.  
Replication testing was then carried out for signals that were either genome-wide 
significant (p<5*10
-8
) in any analysis, or showed suggestive association among those with 
diabetes, motivated by the clinical importance of DKD and the stronger association of the 
known and validated CUBN variant on UACR among those with diabetes.(18) Replication was 
defined as a one-sided p-value <0.05 in the meta-analysis of independent replication studies. Of 
the nine studies that contributed to replication, five studies used imputed dosage, and four 
studies performed replication genotyping of the index SNPs. A meta-analysis of the replication 
results was performed. Subsequently, the double GC-corrected results from the discovery meta-
analysis and the results of the nine replication studies were meta-analyzed to obtain the overall 
statistical significance. Unless stated otherwise, all reported p-values are two-sided. 
Assuming that associated SNPs explain a respective 0.6% and 0.5% of the UACR variance 
in diabetes (Table 1), there was 95% and 91% power, respectively, to replicate the seven 
suggestive loci from the discovery stage in an additional 1,800 samples with a 1-sided p-value 
<0.05. 
 
Additional Analyses to Characterize Novel Loci 
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Replicated SNPs were further evaluated even in the absence of genome-wide significance 
because, in addition to the significant replication p-value, the low heterogeneity across cohorts 
and the biological plausibility of the RAB38 locus further increased confidence in the findings.  
The SNPs were evaluated in the DCCT/EDIC study for association with a primary clinical 
endpoint defined as time from DCCT baseline until time to persistent microalbuminuria or a 
secondary endpoint of time to incident albumin excretion rate >300 mg /24h or end-stage renal 
disease.(10) Time to outcome development or censoring was determined as the number of visit 
years from DCCT baseline up to and including the 12th year of EDIC follow-up. Subjects with 
persistent microalbuminuria at DCCT baseline and DCCT year 1 were excluded from analyses of 
that outcome. 
 Epigenomic map analyses were performed as described previously(19) using data from 
human kidney and kidney proximal tubule epithelial cells that can be accessed at Gene 
Expression Omnibus (GSE49637).  
 Genetic associations with additional renal function traits, estimated glomerular filtration 
rate (eGFR) and CKD, were evaluated based on results from GWAS meta-analysis of the 
corresponding traits within the CKDGen Consortium (personal communication). 
 
Gene Expression Analyses in Human Tissues 
Quantification of transcript abundance in micro-dissected fractions of human glomeruli and 
tubuli from surgical nephrectomies, living allograft donors and portions of diagnostic kidney 
biopsies(20) was carried out using RNA-seq. Tissue from different renal compartments was 
separated using micro-dissection, homogenized and stored at -80°C. Total RNA of human 
proximal tubule fractions (n=256) and glomerular cells (n=48) were isolated using RNeasy Mini 
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Kit (Qiagen) according to manufacturer's instructions. RNA quality was assessed with the Agilent 
Bioanalyzer 2100, and RNA preparations exhibiting RIN scores >7 were used for cDNA synthesis. 
(library preparation at DNA Sequencing Core at UT Southwestern Medical Center). In short, 1 ug 
total RNA was used to isolate poly A purified mRNA using the Illumina TruSeq RNA Preparation 
Kit. Single-end 100bp sequencing was carried out, and the annotated RNA counts (fastq) were 
calculated by Illumina’s CASAVA 1.8.2. Reads were mapped to the reference genome (NCBI build 
37, hg19) using Spliced Transcripts Alignment to a Reference (STAR). Reads per kilobase of 
transcript per million mapped (RPKM) for HS6ST1 and RAB38 were compared between 
glomerular and tubular fractions using a two-sided t-test. 
Comparison of candidate gene expression between cases with biopsy-proven DKD and 
healthy controls was based on publicly available micro-array data from human micro-dissected 
glomeruli and tubuli (Gene Expression Omnibus (GSE 30122).(20) Raw data were analyzed using 
the R package 'Affy' Version 1.44.0, expression levels were normalized using Robust Multi-array 
Average (RMA). Transcript abundance between patients and controls was compared using two-
sided t-tests; statistical significance was defined as p<8.3*10
-3
 (alpha of 0.05 corrected for six 
comparisons). 
 
Studies of Rab38 in Rats 
To better understand the association of RAB38 with albuminuria in diabetes, we studied 
genetically modified rat models of diabetes. Eight Rab38 knockout (KO) rats on a Fawn-hooded 
hypertensive (FHH) background, seven rats transgenic for the wild-type Brown Norway rat 
Rab38 allele, and seven congenic rats were generated and raised as described previously.(21–
23) Rab38 KO rats did not express the protein.(22) These references also describe the recording 
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of blood pressure and the measurement of glucose and albuminuria. Diabetes was induced by 
treating 9-week-old male rats with streptozotocin (STZ, Sigma-Aldrich, St. Louis, MO, 50mg/kg 
i.p.). 
Paraffin blocks of rat kidney samples were sectioned (thickness 6μm) with a Leica 
RM2255 rotary microtome (Thermo-Fisher Scientific, Waltham, MA) on Superfrost Plus glass 
slides (12-550-15, Thermo-Fisher Scientific, Waltham, MA). Before staining, slides were 
deparaffinized in changes of CitriSolv (22-143-975, Thermo-Fisher Scientific, Waltham, MA) and 
70% isopropanol. Antigen retrieval was accomplished by incubating in sodium citrate buffer 
(1.8% 0.1M citric acid, 8.2% 0.1M sodium citrate, in distillated water, pH 6.0) in a rice cooker for 
30 minutes. Slides were blocked with PBS blocking buffer (1% BSA, 0.2% non-fat dry milk in PBS) 
for 30 minutes and stained with primary antibodies specific for megalin or cubilin diluted in 
blocking buffer overnight at 4°C. Sheep anti-megalin and rabbit anti-cubilin were kindly 
provided by Dr. P Verroust, INSERM, Paris, France. After two washes in 0.1% Tween 20 (v/v in 
PBS), slides were incubated with corresponding fluorophore-conjugated secondary antibodies 
(Invitrogen) diluted in blocking buffer at room temperature for 1 hour and counterstained with 
10 μM Hoechst 33342 (Molecular Probes-Invitrogen, H1399). Slides were subsequently 
mounted in Prolong Gold Anti-fade reagent (Invitrogen), acquired on Leica SP5 confocal laser 
scanning microscope (Center for Microscopy and Image Analysis, University of Zurich) equipped 
with a Leica APO 63x NA 1.4 oil immersion objective. 
All experiments were performed in compliance with National Institutes of Health Guide 
for Care and Use of Laboratory Animals, and all used protocols were approved by the local 
Institutional Animal Care and Use Committee. 
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Results  
Discovery of Genomic Loci Associated with Albuminuria Traits  
The discovery GWAS meta-analyses for the four traits included up to 20 studies and up to 
54,450 individuals per trait. The median UACR in the 20 individual studies that contributed to 
the UACR meta-analysis ranged from 2.5 to 15.6 mg/g. Across all studies, the mean proportion 
of women was 53%, and the median of average age was 57 years. The prevalence of diabetes in 
the population-based studies ranged from 1 to 14% (Supplementary Table 1).  
There was no evidence of systematic biases influencing the genome-wide association 
results as indicated by low genomic control parameters (Supplementary Fig. 1). Only SNPs in 
the previously identified CUBN locus showed genome-wide significant association with both 
UACR (p=2.4*10
-10
, Supplementary Table 4, Supplementary Fig. 2) and MA (p=1.3*10
-10
, 
Supplementary Table 5, Supplementary Fig. 2). The effect of the minor C allele of the index SNP 
rs10795433 on logarithmic UACR values was four-fold larger among 5,825 individuals with 
diabetes (0.19 log(mg/g), p=2.0*10
-5
) compared to 46,061 individuals without diabetes (0.045 
log(mg/g), p=6.1*10
-6
, p-value for difference 6.2*10
-3
). This corresponds, for each additional C 
allele, to a 5% higher geometric mean of UACR (exp(0.045)) in non-diabetics compared to 21% 
higher average UACR in diabetics (exp(0.19)). 
Suggestive associations were identified for all four analyses (Supplementary Tables 4–7, 
regional association plots in Supplementary Fig. 3). Among the clinically important group of 
individuals with diabetes, seven genomic loci contained one or more SNPs showing suggestive 
association with UACR. These were exclusively identified in the meta-analysis of individuals with 
diabetes and mapped into or near HS6ST1, CNTN4, KBTBD8, TFAP2B/PKHD1, CHN2, 
WDR11/FGFR2, and RAB38/CTSC (Supplementary Table 7). Following our analytical strategy, we 
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selected the index SNP in each of these seven regions for follow up among up to 1,962 
independent individuals with diabetes.  
The Supplementary PDF document contains the QQ and Manhattan plots of all GWAS 
meta-analyses, the regional association plots, tables with cohort descriptions and association 
results of SNPs at p<10
-5
.  
 
Replication Analyses Implicate RAB38/CTSC and HS6ST1 as Novel Loci for UACR in Diabetes 
The replication analyses included 9 studies and up to 1,962 individuals with diabetes. The 
median UACR across replication studies ranged from 3.8 to 14.5 mg/g. The mean proportion of 
women was 49%, and the median of average age was 55 years. For the seven SNPs tested for 
replication (Supplementary Table 8), we assessed whether the one-sided p-value was <0.05 in 
the combined replication studies (see Methods). This was the case for two SNPs: intergenic 
rs649529 upstream of RAB38/downstream of CTSC on chromosome 11q14 (Fig. 1a) and the 
intronic variant rs13427836 in HS6ST1 on chromosome 2q21 (Fig. 1b). As illustrated in Fig. 1c, 
each additional copy of the minor T allele of rs649529 at RAB38/CTSC was consistently 
associated with lower UACR among the 5,825 individuals in the discovery and 1,962 in the 
replication cohorts (combined p=5.8*10
-7
, Table 1), with no evidence of heterogeneity across 
cohorts (I
2
=0%). This effect corresponded to 13% lower geometric mean of UACR per copy of 
the T allele. Similarly, rs13427836 in HS6ST1 showed consistent effects across cohorts 
(combined p=6.3*10
-7
, Table 1), with each copy of the T allele associated with approximately 
21% higher mean UACR but moderate heterogeneity (I
2
=29.9%, Fig. 1d). 
The association of both rs649529 near RAB38/CTSC and rs13427836 in HS6ST1 was not 
found in individuals without diabetes (p=1.0 and p=0.76, respectively, Table 2). Differences in 
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the association with UACR among those with and without diabetes were significant (t-test for 
difference p=6.9*10
-6
 for rs649529 and p=1.7*10
-5
 for rs13427836). Effects for the index variant 
in CUBN are provided for comparison. We also evaluated the association of the replicated SNPs 
with MA in the setting of diabetes. Information was obtained from a subset of studies with 
sufficiently high numbers of individuals with diabetes and MA (n=2,552; ARIC, CHS, COLAUS, 
EPIC, FHS, KORAF3, KORAF4, and SHIP). Across cohorts, the odds ratio (OR) for MA for each copy 
of the minor allele was 0.84 for rs649529 near RAB38 (p=0.019) and 1.39 for rs13427836 in 
HS6ST1 (p=7.8*10
-4
), consistent with the direction of the SNP effects on UACR.  
 
Characterization of Genetic Effects by Markers of Kidney Function and Diabetes 
Next we investigated whether the gene-by-environment interaction was also observed for the 
eGFR, another measure of kidney function, and/or diabetes or glycemic traits. There were no 
statistically significant associations between rs649529, rs13427836, rs10795433 and eGFR in 
those with diabetes or without diabetes (Table 2), nor any associations with CKD. There were 
also no statistically significant associations of these variants with type 2 diabetes, fasting blood 
glucose, or plasma hemoglobin A1c concentrations (Table 2), indicating that the observed 
associations pertain to albuminuria in the setting of diabetes rather than to diabetes or 
impaired glucose metabolism per se. A comprehensive search in the NHGRI GWAS Catalog(24) 
did not reveal any significant associations between the two validated SNPs or their proxies with 
other diseases or traits. 
 
Variant Evaluation 
Using publicly available data of genetic effects on gene expression,(25) we found an association 
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in cis between rs649529 and transcript levels of both RAB38 (p=5.4*10
-6
) and the neighboring 
CTSC (p=7.6*10
-7
), consistent with a regulatory effect of this variant in whole blood. 
Corresponding data for kidney-specific tissues are currently not available, but we used 
epigenetic maps generated from human adult kidney tissue(19) (see Methods) to further 
examine the regulatory potential of index SNPs. The intronic index SNP in HS6ST1 and several 
proxies mapped into enhancer regions. Similarly, the CUBN index variant rs10795433 mapped 
into an intronic enhancer region. The region in which the index variant at RAB38/CTSC is located 
was annotated as not mapped/repressed in these cells preventing further examination. All 
proxies in strong LD with these three index SNPs (r
2
>0.6, 1000G v5 reference panel)(26) were 
intronic (CUBN and HS6ST1) or intergenic (RAB38/CTSC). 
 
Clinical Characterization Including Gene Expression of Replicated Loci 
In order to evaluate target tissues within the kidney, we characterized the identified loci using 
tissue-specific gene expression data. Clinical characterization was conducted using data from 
patients with DKD and healthy controls(27) and a prospective study of individuals with type 1 
diabetes.(28) 
 We utilized publicly available data(27) to compare relative expression of RAB38, CTSC 
and HS6ST1 between patients with biopsy-confirmed DKD and healthy controls (see Methods). 
After multiple testing correction, only RAB38 expression levels were significantly different, with 
higher expression in tubuli of DKD patients compared to controls (p=1.3*10
-4
, Fig. 2a). We also 
used RNA-seq data from micro-dissected human kidney samples to quantify RAB38 and HS6ST1 
expression in human glomeruli and tubuli. HS6ST1 showed higher expression levels than RAB38, 
and both genes showed higher expression in tubuli than in glomeruli (Fig. 2b). The difference 
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between tubular and glomerular expression was more pronounced for RAB38 (p=1.1*10
-8
) than 
for HS6ST1 (p=0.015).  
 To investigate whether the effect of the replicated SNPs extended to kidney disease 
progression in the setting of type 1 diabetes, the SNPs were tested for association with incident 
MA (268 cases, primary endpoint) and a combined endpoint of time to macroalbuminuria or 
ESRD (133 cases, secondary endpoint) among up to 1,304 participants with type 1 diabetes in 
the DCCT/EDIC Study.(28) Neither SNP showed significant association (Supplementary Table 9). 
 
Diabetic Rab38 Knock-out Rats Show Increased Urinary Albumin Excretion  
We aimed to further substantiate our findings by obtaining experimental support. We focused 
on the examination of RAB38 because it was the gene implicated by higher gene expression in 
tubuli of DKD patients compared to controls, and because previous studies of Rab38 KO and 
transgenic rats have confirmed its role in albuminuria in FHH rats and highlighted a role in 
tubular albumin reuptake.(21,22) We thus examined these animals in the setting of diabetes as 
outlined in Fig. 3a. Injection of streptozotocin (STZ) in 9-week-old rats successfully induced 
diabetes in all strains (Fig. 3b). Blood glucose rose from normal values before injection of STZ 
(congenic 205±3 mg/dL, transgenic 227±11 mg/dL, KO 198±7 mg/dL) to high values that indicate 
severe hyperglycemia one week after STZ (congenic 422±35 mg/dL, transgenic 406±27 mg/dL, 
KO 420±21 mg/dL). At age 11, 12, and 13 weeks, blood glucose levels remained high and 
showed no significant differences between strains (Fig. 3b). There were no significant 
differences in mean arterial blood pressure between congenic, transgenic, and KO animals 
freely moving around the cage; all animal strains showed a tendency towards decreased blood 
pressure 3-4 weeks after injection of STZ (Fig. 3c). 
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As illustrated in Fig. 3d, Rab38 KO animals showed a progressive increase in urinary 
albumin excretion that became statistically significant two weeks after injection of STZ. At 4 
weeks post injection, Rab38 KO animals had an albumin excretion of 79±14 mg/day, whereas 
albumin excretion was only 28±8 mg/day in transgenic (p<0.01) and 41±13 mg/day in congenic 
animals (p<0.01). These data indicate that diabetic rats without Rab38 are more susceptible to 
the development of albuminuria than congenic and transgenic animals with functional Rab38 
despite a similar degree of hyperglycemia in all animals. Kidney sections obtained from a subset 
of animals showed a higher average glomerulosclerosis score (2.9±0.3) compared to congenic 
(2.2±0.1) and transgenic (2.2±0.1) rats (p<0.05, Supplementary Fig. 4), but differences were 
subtler than the ones observed for urinary albumin excretion.  
To further clarify how loss of Rab38 may lead to albuminuria, we performed 
immunohistochemistry staining of megalin and cubilin, known to mediate albumin re-uptake in 
the proximal tubulus, in kidney sections of all three animal strains. There was a marked 
reduction of both cubilin and megalin at the luminal membrane of proximal tubular cells in 
Rab38 KO rats compared to congenic and transgenic control animals (Fig. 3e), consistent with a 
role of Rab38 in regulating the abundance of cubilin and megalin at the cell surface. In contrast, 
there was no significant difference in the number of structures positive for the lysosomal 
marker LAMP1 among the three strains. 
 
Discussion 
In this GWAS discovery meta-analysis of 2,191,945 SNPs in up to 54,450 participants of 20 
studies, we replicated the association of the previously identified CUBN locus and UACR as well 
as MA at genome-wide significance and identified several suggestive signals among individuals 
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with diabetes. Two of these loci, RAB38/CTSC and HS6ST1, showed evidence of independent 
replication and RAB38 was further supported by functional studies in a rat model. Our findings 
point to mechanisms in renal handling of albumin that associate with albuminuria in humans in 
the setting of diabetes. They thus represent examples of gene-by-diabetes interactions resulting 
in a complex trait that manifests when both environmental exposure and genetic susceptibility 
variants occur together.(29) 
 
Not all individuals with diabetes develop DKD, suggesting that neither the presence of 
hyperglycemia nor genetic variants alone are sufficient to elicit the renal damage that typically 
manifests itself as albuminuria in diabetes. Our observations therefore raise the question of 
how the diabetic environment may result in the manifestation of genetic effects on albuminuria. 
The lack of association between both genetic variants and type 2 diabetes or specific glycemic 
measures in humans indicates that their effects occur without influencing diabetes per se. This 
notion is further substantiated by the fact that diabetic Rab38 KO rats showed higher urinary 
albumin concentrations compared to controls despite the presence of similar blood glucose 
concentrations. 
A difference between our observations in humans and rats is that the effect of genetic 
variation near RAB38 on albuminuria was only found in humans with but not without diabetes, 
whereas Rab38 KO rats without diabetes also progress to albuminuria.(22) A potential 
explanation is that KO rats represent a null mutation, allowing for the genetic component to 
take full effect without needing further aggravation by environmental factors. Conversely, many 
human susceptibility variants of complex traits do not result in a complete loss of function but 
instead are of regulatory nature. The effect of such variants may become apparent only upon an 
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environmental challenge, such that genetically determined alterations in renal albumin handling 
could manifest themselves in the setting of hyperglycemia and/or diabetes due to a number of 
mechanisms that secondarily impact albumin reabsorption, including an increased load of 
filtered albumin due to hyperfiltration or impairment of the glomerular filter. Along these lines, 
our observation of significantly higher RAB38 transcript abundance in tubuli of DKD patients 
than controls may indicate an adaption of the tubular machinery for albumin reabsorption in 
this setting. Moreover, genetics effects of the index SNP at the CUBN locus on albuminuria were 
four times as large in individuals with compared to those without diabetes, supporting 
alterations of tubular albumin handling in the setting of diabetes.   
RAB38 encodes a member of the small Rab GTPase protein family that regulate 
intracellular vesicle trafficking between organelles and are important in exo-, endo- and 
transcytosis.(30) Expression of Rab38 at the mRNA and protein level was observed in proximal 
tubule cells of wild-type rats.(31) FHH rats, a natural Rab38 null mutation, show increased 
urinary albumin excretion without changes in their glomerular permeability.(21) In these 
animals, the expression of a Brown Norway Rab38 transgene led to phenotypic rescue, and 
knockdown of Rab38 in a proximal tubule cell system significantly decreased albumin 
endocytosis.(22) Together, these observations support an important role for the small Rab 
GTPase RAB38 in the reabsorption of filtered albumin. 
Impaired RAB38 function may lead to increased albumin excretion via different 
mechanisms: altered intracellular vesicle transport may affect albumin reabsorption or recycling 
of reabsorbed albumin back to the plasma membrane.(32) Alternatively, altered RAB38 function 
may affect the delivery of proteins required for albumin endocytosis such as cubilin or megalin, 
the mechanism underlying albuminuria in Dent’s disease.(33) Our experimental data showing 
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reduced abundance of cubilin and megalin in Rab38 KO but not control rats is consistent with 
the latter hypothesis. Finally, it is also conceivable that impaired RAB38 function may directly 
cause glomerular damage, in turn leading to increased concentrations of urinary albumin.  
Although the combined evidence from Rab38 KO rats along with the gene expression 
and GWAS data strongly implicate RAB38 as the gene underlying albuminuria in humans, the 
intergenic index SNP mapped upstream of RAB38 and downstream of CTSC and was found to 
associate with transcript levels of both genes in whole blood. We can therefore not exclude the 
possibility that CTSC may be the causal gene underlying the observed associations, or that it 
contributes to the phenotype in addition to RAB38. CTSC encodes for a lysosomal cysteine 
protease. Rare mutations in the gene cause autosomal-recessive Papillon-Lefevre syndrome. No 
renal abnormalities have been reported in affected patients,(34) Ctsc KO mice do not show 
kidney abnormalities,(35) and the gene has not been linked to albuminuria or kidney disease.  
 The other genomic locus associated with albuminuria in diabetes contains HS6ST1, 
encoding the enzyme heparan sulfate (HS) 6-O-sulfotransferase that catalyzes the 6-O-sulfation 
of HS and heparin.(36,37) HS are anionic side-chains of HS proteoglycans, which are 
components of basement membranes, extracellular matrix and cell surfaces. Several studies 
have reported that inactivation or removal of HS lead to proteinuria, and biopsies from diabetic 
patients revealed changes in HS sulfation patterns compared with controls.(38) Thus, a genetic 
variant altering the enzyme’s activity or abundance may lead to altered albuminuria. The 
underlying mechanisms could be manifold, as HS have been reported to not only impact 
glomerular filtration but also affect growth factor signaling, composition and functions of the 
glomerular basement membrane, and functions at the endothelial surface layer(38) and the 
proximal tubule.(39)  
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Strengths of our study include its large sample size, specific examination of individuals with 
diabetes, and consistent effects across a variety of studies underscoring the relevance of our 
findings at the general population level. In addition, we performed careful characterization of a 
replicated finding through in vivo experiments in RAB38 KO and control rats that cannot, 
however, elucidate the exact mechanism by which genetic variation at this locus influences 
albuminuria in humans. Limitations include the fact that the replicated SNPs did not achieve 
genome-wide significance necessitating future confirmation in even larger studies, and that we 
could not assess allele-specific gene expression in human kidney tissues. We focused on 
European Ancestry study participants and mostly on individuals with type 2 diabetes. Future 
studies should therefore examine these associations among individuals of additional ancestries 
and in well-powered studies of patients with type I diabetes. Although results were combined 
after study-specific analyses, biological variation in UACR and different urine collection and 
storage methods may have resulted in increased variation and thus reduced statistical power to 
reveal significant associations. Additional studies are required to determine the causal variants 
and the exact underlying molecular mechanism by which genetic variation at RAB38/CTSC and 
HS6ST1 associates with albuminuria in humans. An elucidation of the underlying mechanisms 
and the contributions and differences of albuminuria of glomerular and tubular origin may 
improve our understanding of proteinuric kidney diseases in general, but may be especially 
relevant to DKD, the most common cause of end-stage renal disease.  
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Fresenius Stiftung (Dr. Iris M. Heid and Dr. Carsten A. Böger: 2012_A147; Dr. Carsten A. Böger 
and Dr. Bernhard K. Krämer: P48/08//A11/08). GENDIAN Study Group: Mathias Gorski, Iris M. 
Heid, Bernhard K. Krämer, Myriam Rheinberger, Michael Broll, Alexander Lammert, Jens 
Brüning, Matthias Olden, Klaus Stark, Claudia Strohmeier, Simone Neumeier, Sarah Hufnagel, 
Petra Jackermeier, Emilia Ruff, Johanna Christ, Peter Nürnberg, Thomas Haak, Carsten A. Böger. 
 
INCIPE Study 
The INCIPE study was co-sponsored by Fondazione Cassa di Risparmio di Verona, Azienda 
Ospedaliera di Verona, and University of Verona, Italy. Nicole Soranzo's research is supported by 
the Wellcome Trust (Grant Codes WT098051 and WT091310), the EU FP7 (EPIGENESYS Grant 
Code 257082 and BLUEPRINT Grant Code HEALTH-F5-2011-282510). 
 
KORA-F3/KORA-F4 Study 
The genetic epidemiological work was funded by the Munich Center of Health Sciences (MC 
Health) as part of LMUinnovativ, and by the Else Kröner-Fresenius-Stiftung (P48/08//A11/08; 
C.A.B., B.K.K; 2012_A147 to CAB and IMH.). The kidney parameter measurements in F3 were 
funded by the Else Kröner-Fresenius-Stiftung (C.A.B., B.K.K.) and the Regensburg University 
Medical Center, Germany; in F4 by the University of Ulm, Germany (W.K.). Denovo genotyping 
as well as partly genome wide genotyping costs in F3 and F4 were funded by the Else Kröner-
Fresenius-Stiftung (C.A.B., B.K.K.). The KORA research platform and the MONICA Augsburg 
studies were initiated and financed by the Helmholtz Zentrum München, German Research 
Center for Environmental Health, by the German Federal Ministry of Education and Research 
and by the State of Bavaria. Genotyping was performed in the Genome Analysis Center (GAC) of 
the Helmholtz Zentrum München. The LINUX platform for computation were funded by the 
University of Regensburg for the Department of Epidemiology and Preventive Medicine at the 
Regensburg University Medical Center. 
 
LIFELINES Study 
The LifeLines Cohort Study, and generation and management of GWAS genotype data for the 
LifeLines Cohort Study is supported by the Netherlands Organization of Scientific Research NWO 
(grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch 
government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, 
the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of 
Provinces (SNN), the Province of Groningen, University Medical Center Groningen, the 
University of Groningen, Dutch Kidney Foundation and Dutch Diabetes Research Foundation. 
LifeLines is a multi-disciplinary prospective population-based cohort study examining in a unique 
three-generation design the health and health-related behaviours of 165,000 persons living in 
the North East region of The Netherlands. It employs a broad range of investigative procedures 
in assessing the biomedical, socio-demographic, behavioural, physical and psychological factors 
which contribute to the health and disease of the general population, with a special focus on 
multimorbidity and complex genetics. 
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MESA Study 
University of Washington (N01-HC-95159), Regents of the University of California (N01-HC-
95160), Columbia University (N01-HC-95161), Johns Hopkins University (N01-HC-95162, N01-
HC-95168), University of Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), 
Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-95166), New England 
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We owe a debt of gratitude to all participants. We thank the primary care practitioners Raffaela 
Stocker, Stefan Waldner, Toni Pizzecco, Josef Plangger, Ugo Marcadent and the personnel of the 
Hospital of Silandro (Department of Laboratory Medicine) for their participation and 
collaboration in the research project. We thank Dr. Peter Riegler (Hemodialysis Unit, Hospital of 
Merano) for the important discussions. In South Tyrol, the study was supported by the Ministry 
of Health and Department of Educational Assistance, University and Research of the 
Autonomous Province of Bolzano, the South Tyrolean Sparkasse Foundation, and the European 
Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947) 
 
PREVEND Study 
PREVEND genetics is supported by the Dutch Kidney Foundation (Grant E033), the EU project 
grant GENECURE (FP-6 LSHM CT 2006 037697), the National Institutes of Health (grant 
2R01LM010098), The Netherlands organisation for health research and development (NWO-
Groot grant 175.010.2007.006, NWO VENI grant 916.761.70, ZonMw grant 90.700.441), and the 
Dutch Inter University Cardiology Institute Netherlands (ICIN). 
 
SAPHIR Study 
The SAPHIR-study was partially supported by a grant from the Kamillo Eisner Stiftung to B. 
Paulweber and by grants from the "Genomics of Lipid-associated Disorders – GOLD" of the 
"Austrian Genome Research Programme GEN-AU" to F. Kronenberg. 
 
SHIP/SHIP-Trend/GANI_MED Study 
SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, 
which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 
01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the 
Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to 
Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of Education and Research 
(grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of 
Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, 
Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The University of 
Greifswald is a member of the 'Center of Knowledge Interchange' program of the Siemens AG, 
the German Centre for Diabetes Research (DZD), and the Caché Campus program of the 
InterSystems GmbH. The SHIP authors are grateful to Mario Stanke for the opportunity to use 
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his Server Cluster for the SNP imputation as well as to Holger Prokisch and Thomas Meitinger 
(Helmholtz Zentrum München) for the genotyping of the SHIP-Trend cohort. 
 
SKIPOGH Study 
This research was funded by a grant from the Swiss National Science Foundation (33CM30-
124087). The study also received support from Lausanne University Hospital, Geneva University 
Hospital and Bern University Hospital, Switzerland. Murielle Bochud received support from the 
Swiss School of Public Health Plus (SSPH+). 
 
Vanderbilt Study 
Genotyping was supported by NIGMS RC2-GM092318 (Omni1 and Omni5 array). This work was 
supported by the eMERGE Network, initiated and funded by the National Human Genome 
Research Institute, with additional funding from the National Institute of General Medical 
Sciences (NIGMS), through U01-HG04603 (660 array).  
 
Susztak Laboratory 
Work in the laboratory of Katalin Susztak was supported by NIH R01 DK076077 and DK087635. 
 
Jacobs Laboratory 
Work in the Jacobs and Lazar laboratories was supported by 2R01 069321 to HJJ. 
 
Devuyst Laboratory 
This work was supported by the European Community's Seventh Framework Programme 
(FP7/2007-2013) under grant agreement n° 305608 (EURenOmics) and the Swiss National 
Science Foundation project grant 310030_146490. 
 
Additional Data Resources 
Data on glycemic traits have been contributed by MAGIC investigators and have been 
downloaded from www.magicinvestigators.org 
 
Findings from this study were presented at the 51st Congress of the ERA-EDTA in Amsterdam, 
2014, and at the CHARGE Investigator Meeting July 2015 in Jackson, MS. An abstract of this 
work was accepted for platform presentation at the ASHG 2015 Annual Meeting in Baltimore, 
MD. 
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Tables 
 
Table 1: Replicated SNP associations with UACR in individuals with diabetes 
  
sample 
size 
effect on 
log(UACR[mg/g]) s.e. p-value I
2
 % 
rs649529, RAB38 
discovery  5825 -0.15 0.03 9.3E-06 0 
replication  1962 -0.12 0.05 0.02 0 
combined 7787 -0.14 0.03 5.8E-07 0 
rs13427836, HS6ST1 
discovery  5509 0.20 0.04 6.1E-06 10 
replication  1890 0.16 0.07 0.03 58 
combined 7399 0.19 0.04 6.3E-07 30 
For both variants, the effect of each additional copy of the minor allele (T) on UACR was modeled in an 
additive fashion. I
2
 is provided as a measure of heterogeneity across studies. Imputation quality ranged 
from 0.41 to 1.0 for rs649529 and from 0.44 to 1.0 for rs13427836. The variants were directly genotyped 
in four of the replication studies, with a call rate ranging from 0.98 to 1 for rs649529 and of 0.99 for 
rs13427836. s.e.: standard error. The estimated proportion of explained variance in UACR among those 
with diabetes is 0.6% for rs649529 and 0.5% for rs13427836, using the formula 2*MAF*(1-
MAF)*effect
2
/var(log[UACR]), based on the combined effect estimates from Table 1 and the phenotypic 
variance in the large population-based ARIC Study.  
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Table 2: Replicated SNP associations with additional kidney function and diabetes-related traits 
 
rs649529, RAB38/CTSC 
trait n effect (OR) s.e. p-value p-difference* 
UACR, diabetes; log(mg/g) 7787 -0.14 0.03 5.8E-07 
6.9E-06 
UACR, no diabetes; log(mg/g) 45094 -0.004 0.008 0.64 
eGFRcrea, diabetes; log(ml/min/1.73m
2
) 11527 0.003 0.004 0.46 
2.8E-01 
eGFRcrea, no diabetes; log(ml/min/1.73m
2
) 118427 -0.001 0.001 0.59 
CKD (eGFR<60 ml/min/1.73m
2
) 118114 (1.01) 0.02 0.57  
Type 2 diabetes 63390 (1.02) 0.02 0.32   
Fasting Glucose; (mmol/l) 46186 0.003 0.006 0.65   
HbA1c; (%)  46368 0.004 0.004 0.31   
rs13427836, HS6ST1 
trait n effect (OR) s.e. p-value p-difference* 
UACR, diabetes; log(mg/g) 7399 0.19 0.04 6.3E-07 
1.7E-05 
UACR, no diabetes; log(mg/g) 34830 0.010 0.012 0.38 
eGFRcrea, diabetes; log(ml/min/1.73m
2
) 11092 0.008 0.006 0.13 
1.3E-01 
eGFRcrea, no diabetes; log(ml/min/1.73m
2
) 114247 0.000 0.001 0.94 
CKD (eGFR<60 ml/min/1.73m
2
) 113612 (0.97) 0.02 0.23  
Type 2 diabetes 63390 (1.00) 0.03 0.94   
Fasting Glucose; (mmol/l) 46186 -0.005 0.004 0.22   
HbA1c; (%) 46368 0.003 0.005 0.61   
rs10795433, CUBN† 
trait n effect (OR) s.e. p-value p-difference* 
UACR, diabetes; log(mg/g) 5825 0.19 0.04 2.0E-05 
8.2E-04 
UACR, no diabetes; log(mg/g) 46061 0.045 0.01 8.7E-06 
eGFRcrea, diabetes; log(ml/min/1.73m
2
) 11522 0.007 0.005 0.18 
0.19 
eGFRcrea, no diabetes; log(ml/min/1.73m
2
) 118299 0.0007 0.001 0.61 
CKD (eGFR<60 ml/min/1.73m
2
) 118121 (1.04) 0.02 0.08  
Type 2 diabetes 63390 (1.00) 0.03 0.88  
Fasting Glucose; (mmol/l) 46186 -0.003 0.005 0.52  
HbA1c; (%) 46368 -0.002 0.005 0.73  
Effects represent the change in trait associated with each additional copy of the minor allele for each of 
the SNPs. For continuous traits, units are provided; the effect for binary outcomes, shown in 
parentheses, represents an odds ratio (OR). Estimates refer to the discovery samples of the respective 
trait and to the published resources for the glycemic traits. Fasting glucose and HbA1c were evaluated 
among individuals free of diabetes. For the kidney traits, p-values and standard errors are corrected 
using genomic control. *P-value for difference from a two-sample t-test: t = (effectDM - effectnonDM) / 
(s.e.DM
2
 + s.e.nonDM
2
) which, for large sample sizes is distributed as a Normal (0,1). The correlation 
between effectDM and effectnonDM is assumed to be 0. s.e.: standard error. †Effect estimates for CUBN are 
provided from the discovery stage. 
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Associations with type 2 diabetes were tested using the publicly available summary statistics dataset 
from the DIAGRAM Consortium (12,171 cases and 56,862 controls).(40) Associations with fasting glucose 
and plasma hemoglobin A1c concentrations were evaluated using the publicly available results from the 
MAGIC Consortium (www.magicinvestigators.org).(41,42) 
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Figure Legends 
 
Figure 1: Overview of associated genomic loci at RAB38/CTSC and HS6ST1 and consistent 
association with albuminuria in diabetes across the contributing studies. (a) Regional 
association plot of the RAB38/CTSC locus on chromosome 11 (b) The T allele at rs649529 is 
associated with lower UACR across discovery and replication studies (c) Regional association 
plot of the HS6ST1 locus on chromosome 10 (d) The T allele of intronic rs13427836 is associated 
with higher UACR across discovery and replication studies. 
 
Figure 2: RAB38 and HS6ST1 expression across kidney tissues. (a) Comparison of RAB38 and 
HS6ST1 expression (microarray) in tubuli and glomeruli of patients with DKD and controls shows 
significantly higher RAB38 expression in tubuli of DKD patients than in tubuli of controls 
(significance threshold 0.05/6=8.3*10
-3
 for investigating RAB38, CTSC and HS6ST1 in tubuli and 
glomeruli). CTSC expression was not significantly different between DKD cases and controls in 
tubuli (p=0.11) or glomeruli (p=0.03). Expression levels are shown as RMA-processed gene 
intensity values. Error bars correspond to the standard error of the mean (s.e.m.). (b) RAB38 
and HS6ST1 transcript abundance quantified from RNA-seq is detected at high levels in human 
tubuli but also in glomerular cells. Transcripts were quantified by reads per kilobase of 
transcript per million mapped (RPKM). Error bars correspond to the standard error of the mean 
(s.e.m.).  
 
Figure 3: Comparison of Rab38 congenic, transgenic and KO rats after induction of diabetes. 
(a) Experimental setup and timeline (b) Comparison of blood glucose concentrations (c) 
Comparison of mean arterial pressure (d) Comparison of urinary albumin concentrations (e) 
Expression of endocytic markers. Immunofluorescence staining for megalin (green, top panel) 
and cubilin (red, bottom panel) in kidneys from all three rat strains. Nuclei counterstained with 
DAPI (blue). Scale bar, 50 μm. Data are presented as mean ± standard error of the mean (SEM). 
The results for blood pressure measurement, urinary albumin excretion, and blood glucose 
were analyzed by two-way ANOVA followed by Tukey’s post hoc test.  
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Genome-wide Association Studies Identify Genetic Loci Associated with 
Albuminuria in Diabetes 
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Supplementary Figure 1: QQ plots for all GWAS meta-analyses 
 
Quantile-quantile (QQ) plots of the GWAS meta-analysis results for (a) the urinary albumin-to-
creatinine ratio (UACR) in the overall sample, (b) UACR among those with diabetes (c) UACR 
among those without diabetes, and (d) microalbuminuria (MA) in the overall sample. The 
observed p-values are plotted on the y-axis against their expected distribution under the null 
hypothesis of no association on the x-axis. 
 
Results for all SNPs are shown in black, and results after removal of loci previously known to 
contain trait-associated variants are shown in yellow. Gray bands represent 95% confidence 
intervals. λ: lambda, genomic control parameter; n: sample size.  
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Supplementary Figure 2: Manhattan plots for all GWAS meta-analyses 
 
Manhattan plots of the GWAS meta-analysis results for (a) UACR in the overall sample, (b) UACR 
among those with diabetes, (c) UACR among those without diabetes, and (d) microalbuminuria 
in the overall sample. SNPs are plotted on the x-axis according to their position on each 
chromosome with the -log10(p-value) on the y-axis. The upper solid horizontal line indicates the 
threshold for genome-wide significance, 5*10-8. The lower solid horizontal line for UACR among 
those with diabetes (b) represents the threshold of 1*10-5 applied to select SNPs for replication. 
Genomic loci previously known to contain trait-associated variants are colored in light blue, new 
findings in dark blue. 
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Supplementary Figure 3: Regional association plots 
 
Regional association plots are shown for all loci that contained at least one index SNP associated 
with the trait at p<10-5 after correction for genomic control. Correlation with the index SNP is 
estimated based on the HapMap r22 CEU samples. Plots were generated using the stand-alone 
version of LocusZoom (Pruim RJ et al., Bioinformatics 2010). When association in a genomic 
region was observed with more than one trait, the regional association plot of the trait with the 
lowest p-value is shown. Genetic positions refer to NCBI build 36/hg18 coordinates. 
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Supplementary Figure 4: Evaluation of glomerulosclerosis in Rab38 KO, congenic and transgenic rats.  
Representative images of trichrome-stained glomeruli from Rab38 congenic, KO and transgenic animals. The glomerulosclerosis 
score was determined from left kidneys of 13-week-old rats (n=3 of each strain) as described previously (O’Meara CC et al. JASN, 2011). 
50 to 60 40x magnified cortical glomeruli were imaged and scored, and scores were averaged for each animal. *p<0.05, **p<0.01 KO vs. 
transgenic, ##p<0.01 KO vs. congenic. Glomerulosclerosis was analyzed using one-way ANOVA followed by Tukey’s post hoc test. 
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Supplementary Table 1: Characteristics of the study populations 
 
Study 
UACR  
sample size Women, %  Age (years) 
eGFR <60 
(ml/min/1.73m
2
)
1
  HTN, % DM, % 
UACR (mg/g) 
(median, 25th%, 
75th%) MA, %  
Disovery cohorts                 
3C 1072 63.6 77.8 (4.8) 19.9 74.4 12.3 5.3 (2.6, 10.7) 11.7 
Advance 2203 32.8 66.7 (6.76) 14.7 47.6 100 15.6 (6.44, 54.8) 45 
AGES 3196 58 76.4 (5.46) 24.2 80.6 11.5 2.66 (1.2, 7.0) 11.9 
Amish** 727 48.9 49.5 (16.9) 3.1 18.9 1.7 7 (4.3, 13.5) NA 
ARIC 7243 53.1 61.8 (6.1) 8.7 40.7 14.2 5.3 (3.0, 9.5) 9.4 
BLSA** 361 46.1 70.4 (15.2) 17.4 21.9 7.7 7 (4.4, 11.0) NA 
CHS 1865 61.3 71.9 (5.0) 9.5 51.4 11 9.3 (5.3, 19.9) 23 
COLAUS 5311 53.2 53.4 (10.8) 3.8 36.1 9.6 5.1 (3.4, 9.1) 9.5 
CROATIA-SPLIT** 472 59.8 49.3 (14.65) 5 39.4 5 2.5 (1.3, 5.8) 7.8 
EPIC 2371 53.3 59.2 (9.00) 29.87 49.3 3 3.6 (1.5, 8.3) 8.1 
Fenland** 1398 56.2 44.9 (7.3) 0.9 18.9 1.4 4.5 (3.2, 7.1) 5.5 
FHS 6523 54.3 51.2 (14.0) 10.7 57.5 9.7 4.58 (2.62, 9.89) 9.69 
INCIPE** 940 52.7 61.0 (11.0) 8.6 69.6 10.6 NA* 7.4 
KORA-F3 1530 50.5 62.5 (10.1) 10.8 41.1 11.1 4.9 (2.1, 11.1) 12.5 
KORA-F4 1804 51.3 60.9 (8.9) 7 20.9 9.2 6.1 (3.8, 11.9) 12.5 
LIFELINES 8085 57.2 47.4 (11.2) NA 31.5 2.2 3.12 (2.2, 4.7) 2.4 
MESA 2511 52.3 62.67 (10.2) 9.72 38.6 5.99 4.60 (3.10, 8.50) 9.52 
MICROS** 504 56.5 46.2 (16.1) 3.8 37.7 4.3 6.0 (4.0, 9.0) 5.4 
PREVEND 3634 48.4 49.6 (12.5) 3.3 31.8 3.4 7.9 (5.0, 15.5) 10.2 
SHIP 2655 51.7 54.5 (15.3) 7.7 51.1 11.2 8.95 (5.00, 20.59) 25.2 
SHIP-TREND** 985 56.2 50.1 (13.7) 4.3 39.6 1.8 6 (3.9, 10.3) 8.5 
Total 55390 
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Replication cohorts                 
ESTHER 2958 55.6 61.87 15.7 57.52 15.87 9.8 (6.2, 19.7) 23.06 
GANI_MED 1674 44.0 60.0 36.1 71.2 24.9 11.8 (6.1, 43.9) 37.2 
GENDIAN 450 47.1 65.05 32.3 53 100 7.54 (3.57,23.65) 27.6 
KORAF4 non-GWAS 1195 52.4 49.2 5.8 13.3 4 5.7 (3.5, 11.4) 23.6 
KORAF3 non-GWAS 1389 52.5 51.7 2.6 29.4 5.1 4.4 (1.87, 9.6) 11 
SAPHIR 1690 37.1 51.4 6.9 55.7 3.3 3.8 (2.3, 8.3) 9.9 
SKIPOGH** 807 52.3 47.1 5.7 22.9 4.5 4.2 (2.7, 7.7) 5.7 
Vanderbilt Omni1 472 47.3 54.5 27.7 70.5 18 11.5 (6.0, 39.0) 36.7 
Vanderbilt Omni5 144 46.9 50.5 21.7 58.2 33.3 14.5 (6.0, 42.2) 35.4 
Vanderbilt 660W 365 56.5 56.5 20.6 57.2 17.9 9.0 (5.0, 26.0) 30.7 
Total 11144               
         *Because of the lower detection limit of the assay, the INCIPE Study only contributed to analyses of MA. 
  **Studies that did not contribute data for analyses of MA or UACR among those with diabetes because of low case numbers. 
1
Timepoint of serum creatinine measurement can differ from that of urinary albumin measurements in some of the studies. 
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Supplementary Table 2: Information about study design and UACR measurement 
 
Study Study Design Total 
genotyped 
sample size 
Study exclusions or disease enrichment, 
and data quality control 
Urinary albumin measurements + QC Key Study References 
Discovery study  
3C Prospective 
population-
based 
1072 Study exclusions or disease enrichment: 
none. Exclusions. none. 
At 4-year follow-up, urinary albumin and 
creatinine were measured in a fresh 
morning urine sample in a single 
laboratory using an immunoturbidimetric 
assay for albumin and Jaffe method for 
creatinine. 
1. The 3C Study Group. Vascular factors 
and risk of dementia. Design of the 
Three-City Study and baseline 
characteristics of the study population. 
Neuroepidemiology. 2003; 22:316-325.  
2. Lambert J-C, Heath S, Even G, 
Campion D, Sleegers K, Hiltunen M, 
Combarros O, Zelenika D, Bullido MJ, 
Tavernier B, Letenneur L, Bettens K, 
Berr B, Pasquier F, Fiévet N, Barberger-
Gateau P, Engelborghs S, De Deyn P, 
Mateo I, Franck F, Helisalmi S, Porcellini 
E, Hanon O, the European Alzheimer’s 
Disease Investigators, De Pancorbo 
MM, Lendon C, Dufouil C, Jaillard C, 
Leveillard T, Alvarez V, Bosco P, 
Mancuso M, Panza F, Nacmias B, Bossù 
P, Piccardi P, Annoni G, Seripa D, 
Galimberti D, Hannequin D, Licastro F, 
Soininen H, Ritchie K, Galan P, 
Dartigues J-F, Tzourio C, Gut I, Van 
Broeckhoven C, Alpérovitch A, Lathrop 
M, Amouyel P. Genome-wide 
association study identifies variants at 
CLU and CR1 associated with 
Alzheimer's disease.  Nat Genet. 
2009;41:1094-9. 
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Advance Randomized 
controlled trial 
2203 Study exclusions or disease enrichment: 
multicenter trial done by 215 collaborating 
centres in 20 countries, including 11,140 
type 2 diabetes subjects all of Caucasian 
origin. Exclusions: 8829 with no genotype; 
10 samples excluded due to sex mismatch, 
high sample missingness or having <0.8 of 
Caucasian ethnicity (STRUCTURE 2.3). Of 
the 2301 remaining samples of good 
genotype quality, 98 did not have data for 
UACR. 
Urinary albumin and creatinine were 
measured in the same morning fresh 
sample in local certified laboratoires 
using local regulations in 20 countries. 
Units were harmonized centrally by the 
George Insitute. Two samples were 
required for the determination of the 
stage of albuminuria. UACR were 
repeated every 6 months during a 5-year 
follow-up. 
1. Ninomiya T et al. Albuminuria and 
kidney function independently predict 
cardiovascular and renal outcomes in 
diabetes. J Am Soc Nephrol. 2009 
Aug;20(8):1813-21.  
2. Patel A et al for the ADVANCE 
Collaborative Group. Effects of a fixed 
combination of perindopril and 
indapamide on macrovascular and 
microvascular outcomes in patients 
with type 2 diabetes mellitus (the 
ADVANCE trial). Lancet 2007; 370: 829-
40. 
AGES Population-
based 
3196 Study information or disease enrichment: 
none. Exclusions: exclusion criteria 
included sample failure, genotype 
mismatch with reference panel, and sex 
mismatch, resulting in clean genotype data 
on 3,219 individuals. 
Urinary albumin was measured in a 
morning urine sample using the 
Tina-quant immunoturbimetric assay 
(Roche Diagnostics, Mannheim). The 
intra-assay CV was 7.2%. Urinary 
creatinine in the same samples was 
measured using the HiCo Creatinine Jaffe 
method (Roche Diagnostics, Mannheim). 
The intra-assay CV was 4.2%. 
Harris TB, Launer LJ, Eiriksdottir G, 
Kjartansson O, Jonsson PV, Sigurdsson 
G, Thorgeirsson G, Aspelund T, Garcia 
ME, Cotch MF, Hoffman HJ, Gudnason 
V.Age, Gene/Environment 
Susceptibility-Reykjavik Study: 
multidisciplinary applied phenomics. 
Am J Epidemiol. 2007 May 
1;165(9):1076-87.  
Amish Population-
based 
"founder" 
cohort 
727 Study information or disease enrichment: 
none. Exclusions: age < 20, severe chronic 
disease, call rate < 95%. 
Urinary albumin concentration was 
measured from stored samples using a 
quantitative immunoturbimetric assay 
(Roche Diagnostics, Indianapolis), and 
creatinine in urine was measured using a 
modified Jaffe method. 
1. Mitchell BD et al. The genetic 
response to short-term interventions 
affecting 
cardiovascular function: rationale and 
design of the Heredity and Phenotype 
Intervention (HAPI) Heart Study. Am. 
Heart J. 155, 823-828 (2008).  
2. Rampersaud E et al. The association 
of coronary artery calcification and 
carotid artery intima-media thickness 
with distinct, traditional coronary 
artery disease risk factors in 
asymptomatic adults. Am. J. Epidemiol. 
168, 1016-1023 (2008). 
Page 64 of 86Diabetes
 22 
ARIC Prospective, 
population-
based 
7243 Study information or disease enrichment: 
none. Exclusions: of the 9713 genotyped 
individuals of European ancestry, we 
excluded 658 individuals based on 
discrepancies with previous genotypes, 
disagreement between reported and 
genotypic sex, one randomly selected 
member of a pair of first-degree relatives, 
or outlier based on measures of average 
DST or more than 8 SD away on any of the 
first 10 principal components. Additional 
samples were excluded for this analysis 
because of the unavailability of the 
phenotype. 
Using stored specimen from samples 
collected at visit 4, urinary albumin was 
measured by a nephelometric method 
either on the Dade Behring BN100 or on 
the Beckman Image 
Nephelometer. Urinary creatinine was 
measured using the Jaffe method. 
The Atherosclerosis Risk in 
Communities (ARIC) Study: design and 
objectives. The ARIC investigators. Am J 
Epidemiol. 1989 Apr;129(4):687-702. 
BLSA Population-
based 
361 Study information or disease enrichment: 
none. Exclusions: non-European descent or 
with missing UACR information. 
Urinary measurements were conducted 
on 24-hour urine samples. Urinary 
albumin was determined with 
nephelometry (Beckman Array System). 
Urinary creatinine was measured using a 
Vitros enzymatic assay (Johnson & 
Johnson Co., Rochester, NY). 
Shock NW et al. Normal Human Aging: 
The Baltimore Study of Aging. 1984. 
CHS Prospective 
population-
based 
1865 Study information or disease enrichment: 
A total of 1908 persons were excluded 
from the GWAS study sample due to the 
presence at study baseline of coronary 
heart disease, congestive heart failure, 
peripheral vascular disease, valvular heart 
disease, stroke or transient ischemic attack 
or lack of available DNA. Exclusions: The 
present report is based upon genotyping 
results from 3,329 CHS Caucasian 
participants, who were free of clinical 
cardiovascular disease at baseline, 
consented to genetic testing, and had DNA 
available for genotyping. Genotypes were 
called using the Illumina BeadStudio 
software. Genotyping was successful in 
3,291 persons.  
Urinary parameters were measured from 
a morning urine sample. The albumin 
was measured by rate nephelometry 
(Array 
360 CE Protein Analyzer, Beckman 
Instruments, Fullerton, CA). The 
creatinine was measured using a Kodak 
Ektachem 700 Analyzer (Eastman Kodak 
company, Rochester, NY). 
1. Fried LP, Borhani NO, Enright P, 
Furberg CD, Gardin JM, Kronmal RA, 
Kuller LH, Manolio TA, Mittelmark MB, 
Newman A, et al. The Cardiovascular 
Health Study: design and rationale. Ann 
Epidemiol. 1991;1(3):263-276.  
2. Heard-Costa, NL et al. NRXN3 is a 
novel locus for waist circumference: a 
genome-wide association study from 
the CHARGE Consortium. 2009. Plos 
Genet. 5(6): e1000539.  
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COLAUS Population-
based 
5311 Study exclusions or disease enrichment: 
none. Exclusions: samples with call rate < 
90% and related individuals. 
Urinary albumin was measured using a 
Bromocresol green assay (Roche 
Diagnostics, Basel, Switzerland). The 
inter- and intra-assay CVs were 2.5% and 
0.4%. Urinary creatinine was measured 
using a Jaffe kinetic compensated 
method. The inter- and intra-assay CVs 
were 2.9% and 0.7%. 
Firmann M, Mayor V, Vidal PM, Bochud 
M, Pécoud A, Hayoz D, Paccaud F, 
Preisig M, Song KS, Yuan X, Danoff TM, 
Stirnadel HA, Waterworth D, Mooser V, 
Waeber G, Vollenweider P. The CoLaus 
study: a population-based study to 
investigate the epidemiology and 
genetic determinants of cardiovascular 
risk factors and metabolic 
syndrome.BMC Cardiovasc Disord. 
2008 Mar 17;8:6. doi: 10.1186/1471-
2261-8-6.  
CROATIA-SPLIT Population-
based 
472 Study exclusions or disease enrichment: 
none. Exclusions: missing UACR levels. 
Urinary albumin excretion was 
measured, in stored urine samples, by an 
automated assay based on a turbimetric 
method with automatic calibration and 
quality control (Synchron CX System, 
Beckman Coulter). 
"10001 Dalmatiians" Croatia launches 
its national biobank Rudan I, Marusić A, 
Janković S, Rotim K, Boban M, Lauc G, 
Grković I, Dogas Z, Zemunik T, Vatavuk 
Z, Bencić G, Rudan D, Mulić R, Krzelj V, 
Terzić J, Stojanović D, Puntarić D, Bilić 
E, Ropac D, Vorko-Jović A, Znaor A, 
Stevanović R, Biloglav Z, Polasek 
O.Croat Med J. 2009 Feb;50(1):4-6. 
EPIC Population-
based 
2371 Study exclusions or disease enrichment: 
participants taking colchicine, probenecid 
or allopurinol at 1st, 2nd health checks or 
3rd follow-up; gout from hospital discharge 
ICD10 M10, between 1997-2008. 
Exclusions: none. 
Urinary albumin was measured in spot 
urine by immunonephelometry using the 
Nephelometer II analyzer (Dade Behring, 
Marburg, Germany). The intra-assay CV 
was 2.91%. Urinary creatinine was 
measured by means of colorimetry using 
the Dimension AR Analyzer (Dade 
Behring Marburg, Germany). 
1. Day N et al. EPIC-Norfolk: study 
design and characteristics of the 
cohort. European Prospective 
Investigation of Cancer. Br J Cancer 80 
Suppl 1, 95-103 (1999). 
2. Lee CT et al. Cross-sectional 
association between fish consumption 
and albuminuria: the European 
Prospective Investigation of Cancer-
Norfolk Study. Am J Kidney Dis 52, 876-
86 (2008). 
Fenland Population-
based 
1398 Study exclusions or disease enrichment: 
exclusion criteria for the study were: 
age<30 or age>55, prevalent diabetes, 
pregnant and lactating women, inability to 
participate including terminal illness, 
psychotic illness, or inability to walk 
unaided. Exclusions: 102 exluded due to 
call rate < 95%, heterozygosity check 
(upper bound 0.2882, lower bound 0.2735), 
relatedness check and duplicate check. 
Using stored samples, urinary albumin 
was measured by means of 
immunonephelometry using the 
Nephelometer II analyzer (Dade Behring, 
Marburg, Germany; intra-assay CV 
2.91%). 
Urinary creatinine was measured 
through colorimetry using the Dimension 
AR Analyzer (Dade Behring Marburg, 
Germany). 
Willer CJ, Speliotes EK, Loos RJ et al. 
(2009) Six new loci associated with 
body mass index highlight a neuronal 
influence on body weight regulation. 
Nat Genet, 41(1): 25-34. 
Page 66 of 86Diabetes
 24 
FHS Prospective 
family-based 
6523 Study exclusions or disease enrichment: 
none. Exclusions: Of the 9,274 participants 
who underwent genotyping, we made the 
following exclusions: sample call rate <97% 
(n=666), genotype heterozygosity > 5 
standard deviations, and ambiguous family 
data (n=127).  This resulted in a total of 
8,481 genotyped individuals. Of them, 1958 
did not have the phenotype available. 
Urinary albumin was measured from 
stored samples using a Tina-quant 
immunoturbimetric assay (Roche 
Diagnostics, Indianapolis, Indiana). The 
intra-assay CV was 7.2% for the Offspring 
cohort and 2.1% for the Third 
Generation.  Urinary creatinine was 
measured using a modified Jaffe method. 
Its intra-assay CV was 2.3% for the 
Offspring cohort and 1.0% for the Third 
Generation cohort. 
1. Feinleib M, Kannel WB, Garrison RJ, 
McNamara PM, Castelli WP. The 
Framingham Offspring Study. Design 
and preliminary data. Prev Med. 
1975;4:518-525.  
2. Kannel WB, Feinleib M, McNamara 
PM, Garrison RJ, Castelli WP. An 
investigation of coronary heart disease 
in families. The Framingham offspring 
study. Am J Epidemiol. 1979;110:281-
290.  
3. Splansky GL, Corey D, Yang Q, 
Atwood LD, Cupples LA, Benjamin EJ, 
D'Agostino RB, Sr., Fox CS, Larson MG, 
Murabito JM, O'Donnell CJ, Vasan RS, 
Wolf PA, Levy D. The Third Generation 
Cohort of the National Heart, Lung, and 
Blood Institute's Framingham Heart 
Study: design, recruitment, and initial 
examination. Am J Epidemiol. 
2007;165:1328-1335. 
INCIPE Cross-
sectional, 
population 
based 
940 Study exclusions or disease enrichment:  
individuals <40 year old. Exclusions: 
pregnant women 
Using stored specimen, urinary albumin 
was measured by a nephelometric 
method. Urinary creatinine was 
measured using the Jaffé method. 
Gambaro, G. et al. Prevalence of CKD in 
northeastern Italy: results of the INCIPE 
study and comparison with NHANES. 
Clin. J. Am. Soc. Nephrol. 5, 1946-1953 
(2010).  
KORA-F3 Prospective 
population-
based 
1530 Study exclusions or disease enrichment: 
none. Exclusions: none. 
Using stored urine samples, 
urinary albumin concentration was 
measured with a latex enhanced 
nephelometric assay (Siemens 
Healthcare Diagnostics) on a Dade 
Behring BN2 apparatus. Urinary 
creatinine concentration was measured 
using an enzymatic method. 
1. Baumeister SE, Böger CA, Krämer BK, 
Doring A, Eheberg D, Fischer B, John J, 
Koenig W & Meisinger C: Effect of 
chronic kidney disease and comorbid 
conditions on health care costs: A 10-
year observational study in a general 
population. Am J Nephrol 31: 222-229, 
2010. 
2. Wichmann HE, Gieger C & Illig T: 
KORA-gen--resource for population 
genetics, controls and a broad 
spectrum of disease phenotypes. 
Gesundheitswesen 67 Suppl 1: S26-30, 
2005. 
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KORA-F4 Prospective 
population-
based 
1804 Study exclusions or disease enrichment: 
none. Exclusions: none. 
Using stored urine samples, 
urinary albumin concentration was 
measured with a latex enhanced 
nephelometric assay (Siemens 
Healthcare Diagnostics) on a Dade 
Behring BN2 apparatus. Urinary 
creatinine concentration was measured 
using a kinetic Jaffe method in KORA F4. 
1. Baumeister SE, Böger CA, Krämer BK, 
Doring A, Eheberg D, Fischer B, John J, 
Koenig W & Meisinger C: Effect of 
chronic kidney disease and comorbid 
conditions on health care costs: A 10-
year observational study in a general 
population. Am J Nephrol 31: 222-229. 
2. Wichmann HE, Gieger C & Illig T: 
KORA-gen--resource for population 
genetics, controls and a broad 
spectrum of disease phenotypes. 
Gesundheitswesen 67 Suppl 1: S26-30, 
2005. 
LIFELINES 3-generations, 
population-
based 
8085 Study exclusions or disease enrichment: 
living outside the 3 Northern provinces of 
The Netherlands. Exclusions: none. 
Urinary albumin and creatinine were 
measured using the Roche Modular. 
Stolk RP, Rosmalen JGM, Postma DS, de 
Boer RA, Navis G, Slaets JPJ, Ormel J, 
and Wolffenbuttel BHR. Universal risk 
factors for multifactorial diseases: 
LifeLines: a three-generation 
population-based study. Eur. J. 
Epidemiol., vol. 23, no. 1, pp. 67–74, 
Jan. 2008.  
MESA Community-
based cohort 
study 
2511 Study exclusions or disease enrichment: 
none. Exclusions: none. 
Urine albumin and creatinine were 
measured at the Clinical Chemistry 
Laboratory at Fletcher Allen Health Care 
(Burlington, Vt). Urine albumin and 
creatinine were measured by 
nephelometry and the rate Jaffe 
reaction, respectively. 
Bild DE et al. Multi-ethnic study of 
atherosclerosis: objectives and design. 
Am J Epidemiol 156, 871-81 (2002). 
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MICROS Cross-
sectional, 
population-
based study 
using 
extended 
pedigrees 
504 Study exclusions or disease enrichment: 
<18 years of age. Exclusions: samples with 
overall SNP call rate < 95%, showing excess 
of heterozygosity, or being classified as 
outliers by IBS clustering analysis were 
excluded prior to further analyses. 
The urinary albumin-to-creatinine ratio 
was measured on a point-of-care 
diabetes management platform (Bayer 
DCA 2000+ analyzer). 
1. Pattaro C, Marroni F, Riegler A, 
Mascalzoni D, Pichler I, Volpato CB, Dal 
Cero U, De Grandi A, Egger C, Eisendle 
A, Fuchsberger C, Gögele M, Pedrotti S, 
Pinggera GK, Stefanov SA, Vogl FD, 
Wiedermann CJ, Meitinger T, 
Pramstaller PP. The genetic study of 
three population microisolates in South 
Tyrol (MICROS): study design and 
epidemiological perspectives. BMC 
Med Genet. 2007;8:29.  
2. Marroni F, Grazio D, Pattaro C, 
Devoto M, Pramstaller P. Estimates of 
genetic and environmental 
contribution to 43 quantitative traits 
support sharing of a homogeneous 
environment in an isolated population 
from South Tyrol, Italy. Hum Hered. 
2008;65(3):175-82.  
PREVEND Population-
based 
3634 Study exclusions or disease enrichment: 
aged between 28-75 yrs, enriched for 
microalbuminuria. Exclusions: none. 
Urinary albumin was determined from 
fresh urine samples by nephelometry  
(BNII; Dade Behring Diagnostic, Marburg, 
Germany). Intra- and inter-assay 
coefficients of variation were 2.2 and 
2.6%, respectively. 
Hillege HL, Fidler V, Diercks GFH, van 
Gilst WH, de Zeeuw D, van Veldhuisen 
DJ, Gans ROB, Janssen WMT, Grobbee 
DE, and de Jong PE. Urinary albumin 
excretion predicts cardiovascular and 
noncardiovascular mortality in general 
population. Circulation, vol. 106, no. 
14, pp. 1777–82, Oct. 2002. 
SHIP Prospective 
population-
based 
2655 Study exclusions or disease enrichment: 
none. Exclusions: sample call rate < 92%, 
duplicate samples (by IBS estimation), 
individuals with reported / genotyped 
gender mismatch. 
Urinary albumin was measured from 
spot first morning void urine by 
nephelometry (BNII, Dade Behring 
Diagnostica, Marburg, Germany). Intra-
assay and interassay coefficients of 
variation were 4.3% and 4.4%, 
respectively. Urinary creatinine 
concentration was measured using 
Kodak Ektachem dry chemistry (Eastman 
Kodak, Rochester, NY). Intra-assay and 
interassay coefficients of variation were 
0.9% and 2.9%, respectively.  
1. John U et al. Study of Health in 
Pomerania (SHIP). A health 
examination in an east German region: 
objectives and design. Soz 
Praventivmed 46:186-194, 2001. 
2. Völzke H et al. Cohort Profile: The 
Study of Health in Pomerania. Int J 
Epidemiol, vol. 40, no. 2, pp. 294–307, 
Apr. 2011. 
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SHIP-TREND Prospective 
population-
based 
985 Study exclusions or disease enrichment: 
this analysis concerns the subset of 988 
individuals with genotype information. 
Exclusions: sample call rate < 94%, 
duplicate samples (by IBS estimation), 
individuals with reported/genotyped 
gender mismatch.  
In a sample of spot urine, both the 
urinary albumin (intra-assay CV 4.5-7.6% 
for 1.0-24.5 mg/dl) and creatinine (Jaffe 
method, intra-assay CV 1.4-2.1% for 5.7-
14.6 mmol/l) were measured on a 
Siemens Dimension Vista 1500 analyzer 
(Siemens Healthcare Diagnostics, 
Marburg, Germany), respectively. 
1. John U et al. Study of Health in 
Pomerania (SHIP). A health 
examination in an east German region: 
objectives and design. Soz 
Praventivmed 46:186-194, 2001. 
2. Völzke H et al. Cohort Profile: The 
Study of Health in Pomerania. Int J 
Epidemiol, vol. 40, no. 2, pp. 294–307, 
Apr. 2011. 
Replication study  
ESTHER Prospective 
study  
2958 Study exclusions or disease enrichment: 
study participants were required to be ≥50 
year old and having a good knowledge of 
the German language. Exclusions: samples 
with insufficient amount of DNA for 
genotyping.  
Urinary albumin concentration was 
measured using nephelometric method 
(Siemens. Marburg, Germany). The 
urinary creatinine levels were 
photometrically measured using the 
modified kinetic Jaffe method (Greiner 
Diagnostic GmbH. Bahlingen, Germany). 
1. Raum E, Rothenbacher D, Low M, 
Stegmaier C, Ziegler H, Brenner H. 
Changes of cardiovascular risk factors 
and their implications in subsequent 
birth cohorts of older adults in 
Germany: a life course approach. Eur J 
Cardiovasc Prev Rehabil 2007;14:809-
814. 
2. Schottker B, Haug U, Schomburg L, 
et al. Strong associations of 25-
hydroxyvitamin D concentrations with 
all-cause, cardiovascular, cancer, and 
respiratory disease mortality in a large 
cohort study. Am J Clin Nutr 2013. 
3. Weck MN, Stegmaier C, 
Rothenbacher D et al. Epidemiology of 
chronic atrophic gastritis: population-
based study among 9444 older adults 
from Germany. Aliment Pharmacol 
Ther. 2007;26:879-887. 
GANI_MED Cohort study 1674 Study exclusions or disease enrichment:  
six main cohorts: heart failure, stroke, 
periodontal disease, renal insufficiency, 
metabolic syndrome, and fatty liver 
disease. Exclusions: sample call rate < 94%, 
heterozygosity rate > 6SD (MAF > 1%), PCA 
outliers (EV 1-4 > 8SD), duplicate samples 
(by IBS estimation), individuals with 
reported/genotyped gender mismatch.. 
In a sample of spot urine, the urinary 
albumin was measured on a Siemens 
Dimension Vista 1500 analyzer (Siemens 
Healthcare Diagnostics, Marburg, 
Germany). Urinary creatinine was 
measured either by an enzymatic or Jaffe 
method, whereas the analyses were 
adjusted accordingly for the method 
used. 
Grabe HJ, Assel H, Bahls T et al. Cohort 
profile: Greifswald approach to 
individualized medicine (GANI_MED). J. 
Transl. Med. 2014; 12: 144. 
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GENDIAN Cohort study 450 Study exclusions or disease enrichment: 
study on type 2 diabetes patients. 
Exclusions: of the 1,026 subjects 
undergoing genotyping, 53 were excluded 
due to call-rate < 95% (n=22), relatedness 
and duplicates (n=11), gender mismatch 
(n=16), ethnicity check (n=4); in addition, 
we excluded the following patients for the 
current analysis of cross-sectional UACR: 
patients with end-stage renal disease 
(n=438) or advanced, histologically proven 
diabetic nephropathy (n=84) or missing 
phenotype (n=1). 
Urinary creatinine was measured using 
an enzymatic assay, urinary albumin was 
measured using the Roche Tina Quant 
assay. 
1. Böger CA et al: effect of ACE and AT-
2 inhibitors on mortality and 
progression to microalbuminuria in a 
nested case control study of diabetic 
nephropathy in diabetes mellitus type 
2: results from the GENDIAN study. Int 
J Clin Pharmacol Ther 2006;44:364-74. 
2. Böger CA et al. Association of eGFR-
related loci identified by GWAS with 
incident CKD and ESRD. Plos Genet 
2011;7:e1002292. 
KORAF4 non-GWAS Prospective 
population-
based 
1195 Study exclusions or disease enrichment: 
none. Exclusions: none. 
Using stored urine samples, 
urinary albumin concentration was 
measured with a latex enhanced 
nephelometric assay (Siemens 
Healthcare Diagnostics) on a Dade 
Behring BN2 apparatus. Urinary 
creatinine concentration was measured 
using an enzymatic method. 
1. Baumeister SE, Böger CA, Krämer BK, 
Doring A, Eheberg D, Fischer B, John J, 
Koenig W & Meisinger C: Effect of 
chronic kidney disease and comorbid 
conditions on health care costs: A 10-
year observational study in a general 
population. Am J Nephrol 31: 222-229, 
2010. 
 2. Wichmann HE, Gieger C & Illig T: 
KORA-gen--resource for population 
genetics, controls and a broad 
spectrum of disease phenotypes. 
Gesundheitswesen 67 Suppl 1: S26-30, 
2005. 
KORAF3 non-GWAS Prospective 
population-
based 
1389 Study exclusions or disease enrichment: 
none. Exclusions: none. 
Using stored urine samples, 
urinary albumin concentration was 
measured with a latex enhanced 
nephelometric assay (Siemens 
Healthcare Diagnostics) on a Dade 
Behring BN2 apparatus. Urinary 
creatinine concentration was measured 
using a kinetic Jaffe method in KORA F4. 
1. Baumeister SE, Böger CA, Krämer BK, 
Doring A, Eheberg D, Fischer B, John J, 
Koenig W & Meisinger C: Effect of 
chronic kidney disease and comorbid 
conditions on health care costs: A 10-
year observational study in a general 
population. Am J Nephrol 31: 222-229, 
2010. 
 2. Wichmann HE, Gieger C & Illig T: 
KORA-gen--resource for population 
genetics, controls and a broad 
spectrum of disease phenotypes. 
Gesundheitswesen 67 Suppl 1: S26-30, 
2005. 
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SAPHIR Healthy 
working 
population 
1690 Study exclusions or disease enrichment: 
none. Exclusions: none. 
Urinary creatinine was measured using a 
modified kinetic Jaffe reaction (CREA, 
Roche Diagnostics GmbH, Mannheim, 
Germany). Urinary albumin 
concentration was determined using the 
Tinaquant assay (Roche Diagnostics 
GmbH, Mannheim, Germany). 
1. Heid IM, Wagner SA, Gohlke H, 
Iglseder B, Mueller JC, Cip P, Ladurner 
G, Reiter R, Stadlmayr A, Mackevics V, 
Illig T, Kronenberg F, Paulweber B:  
Genetic architecture of the APM1 gene 
and its influence on adiponectin 
plasma levels and parameters of the 
metabolic syndrome in 1,727 healthy 
Caucasians. Diabetes 55:375-384, 2006. 
2. Kollerits B, Coassin S, Kiechl S, Hunt 
SC, Paulweber B, Willeit J, Brandstätter 
A, Lamina C, Adams TD, Kronenberg F:  
A common variant in the adiponutrin 
gene influences liver enzyme levels.  
Journal of Medical Genetics 47:116-
119, 2010.  
SKIPOGH Cross-
sectional 
family-based 
population-
based  
807 Study exclusions or disease enrichment: 
none. Exclusions: of the 941 participants 
who underwent genotyping, we excluded 
71 participants with call rate < 90%, 
resulting in a total of 870 genotyped 
individuals. 
Urinary creatinine was measured using 
an IDMS-traceable Jaffe kinetic 
compensated method. Urinary albumin 
concentration was measured using a 
quantitative immuno-nephelometry. 
Pruijm M, Ponte B, Ackermann D, 
Vuistiner P, Paccaud F, Guessous I, 
Ehret G, Eisenberger U, Mohaupt M, 
Burnier M, Martin PY, Bochud M. Eur 
Radiol. 2013 May 28. [Epub ahead of 
print]. 
Vanderbilt Omni1 Practice-based 
cohort 
472 Study exclusions or disease enrichment: 
samples chosen based on being a case or 
control for one of 31 pharmacogenetic 
analyses. Exclusions: individuals of non-
white ancestry in the electronic medical 
record. Also excluded any lab 
measurements of individuals after initiation 
of dialysis or a kidney transplant. 
The urinary albumin concentration was 
measured using turbidimetric 
immunoassay with endpoint 
determination. Urinary creatinine levels 
were measured using the modified Jaffé 
method.  
 
Vanderbilt Omni5 Practice-based 
cohort 
144 Study exclusions or disease enrichment: 
samples chosen based on being a case or 
control for one of 31 pharmacogenetic 
analyses. Exclusions: individuals of non-
white ancestry in the electronic medical 
record. Also excluded any lab 
measurements of individuals after initiation 
of dialysis or a kidney transplant. 
The urinary albumin concentration was 
measured using turbidimetric 
immunoassay with endpoint 
determination. Urinary creatinine levels 
were measured using the modified Jaffé 
method.  
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Vanderbilt 660W Practice-based 
cohort 
365 Study exclusions or disease enrichment: 
samples chosen for normal cardiac 
conduction, meaning that at some point in 
time they had a normal electrocardiogram 
without the presence of heart disease, 
arrhythmias, or electrocardiographically-
active medications. Exclusions: children 
(age <18) and individuals of non-white 
ancestry in the electronic medical record.  
Also excluded any lab measurements from 
individuals after initiation of dialysis or a 
kidney transplant. At some point in their 
electronic medical record, the patients 
were absent of heart disease, but could 
later develop it. 
The urinary albumin concentration was 
measured using turbidimetric 
immunoassay with endpoint 
determination. Urinary creatinine levels 
were measured using the modified Jaffé 
method.  
Denny JC, Ritchie MD, Crawford DC, 
Schildcrout JS, Ramirez AH, Pulley JM, 
Basford MA, Masys DR, Haines JL, 
Roden DM. Identification of genomic 
predictors of atrioventricular 
conduction: Using electronic medical 
records as a tool for genome science.  
Circulation 2010;122(20):2016-21. 
Clinical characterization study  
DCCT/EDIC Trial of 
patients with 
type I diabetes 
1304 Study exclusions or disease enrichment: 
individuals with insulin-dependent type I 
diabetes mellitus between 1 and 15 years 
of duration, age 13-39 years at enrolment, 
free of advanced diabetes-related 
complications, absence of several 
comorbidities.  Exclusions: Subjects 
meeting the criteria for persistent 
microalbuminuria at DCCT baseline and 
DCCT year 1 (n = 60) were excluded from 
the analyses of the time to incident 
albuminuria. Analyses were restricted to 
individuals of European ancestry. 
The urinary albumin concentration was 
measured from times urine samples 
using a solid-phase fluoroimmunoassay. 
Urinary creatinine levels were measured 
using the Jaffé method. 
1. The Diabetes Control and 
Complications (DCCT) Research Group. 
Effect of intensive therapy on the 
development and progression of 
diabetic nephropathy in the Diabetes 
Control and Complications Trial. Kidney 
Int 1995;47(6):1703–20. 
2. de Boer IH et al. Long-term renal 
outcomes of patients with type 1 
diabetes mellitus and 
microalbuminuria: an analysis of the 
Diabetes Control and Complications 
Trial/Epidemiology of Diabetes 
Interventions and Complications 
cohort. Arch Intern Med. 2011 Mar 
14;171(5):412-20. 
 
  
Page 73 of 86 Diabetes
 31 
Supplementary Table 3: Study-specific information about genotyping, imputation and data management and analysis 
 
Study Name 
Genotyping 
Array type 
Genotype 
calling 
algorithm 
QC filters for genotyped SNPs used 
for imputation (listed are criteria for 
exclusion) 
 No of SNPs 
used for 
imputation  
Imputation 
software, 
version 
Imputation Backbone 
(NCBI build) 
Filtering of 
imputed 
genotypes 
Data 
management 
and statistical 
analysis 
3C 
Illumina 
Human610-Quad 
BeadStudio 
call rate < 98%, pHWE < 10E-6, MAF < 
1% 
                   
492,897  
MACH 
1000 Genomes EUR, Dec 
2010 (Build 37) 
none R and ProbABEL 
Advance 
Affymetrix 5.0 
Affymetrix 6.0 
Affymetrix 
SNPs genotyped on Affymetrix 5.0: 
call rate < 96% (<99% if MAF < 5%); 
SNPs genotyped on Affymetrix 6.0: 
call rate < 97% (<99% if MAF < 5%) 
                   
876,688  
IMPUTE2 
2.1.2 
1000 Genomes CEU Pilot, 
Jun 2010 plus HapMap 3 
rel. 2 all available 
haplotypes, Feb 2009 
(build 36) 
imputation 
info < 0.5 
SNPTEST 
AGES 
Illumina 
Hu370CNV 
Illumina 
call rate < 97%, pHWE < 1e-6, MAF < 
0.01, mishap p < 1e-9, SNPs not in 
Hapmap or strandedness issues 
merging with Hapmap 
                   
329,804  
MACH 
1.0.16 
HapMap rel. 22 (build 36) none 
R,ProbABEL, 
Linear and 
Logistic 
Regression 
Amish Affymetrix 500K BRLMM 
call rate < 95%, pHWE < 10E-6, MAF < 
1%, non-HapMap 
                   
338,598  
MACH 
1.0.15 
HapMap rel. 22 phased 
CEU haplotypes (build 36) 
none 
Measured 
genotype 
accounting for 
polygenic 
component 
ARIC Affymetrix 6.0 Birdseed 
call rate < 95%, pHWE < 10E-5, MAF < 
1% 
                   
669,450  
MACH 
1.0.16 
HapMap rel. 22 (build 36) none 
ProbABEL, PLINK, 
R 
BLSA 
Illumina Infinium 
HumanHap 550K 
Beadstudio 
call rate < 99%, pHWE < 10E-4, MAF < 
1% 
                   
501,764  
MACH 
1.0.15 
HapMap rel. 21 phased 
CEU haplotypes (build 35) 
MAF < 1%, 
r2hat < 0.3 
SAS, Merlin, R 
CHS Illumina 370CNV BeadStudio 
call rate<97%, pHWE<10E-5, 
heterozygotes=0, SNP not in HapMap 
                   
306,655  
BimBam 
0.99 
HapMap rel. 22 (build 36) 
dosage 
variance<0.
01 
Linear and 
logistic 
regression using 
R, robust 
estimates of SE 
COLAUS Affymetrix 500K BRLMM call rate < 70%, pHWE < 10E-7 
                   
390,631  
IMPUTE 
0.2.0 
HapMap rel. 21 (build 35) none Matlab 
CROATIA-
SPLIT 
HAP370CNV Illumina call rate < 98%, pHWE < 10E-10 
                   
330,997  
MACH 
1.0.15 
HapMap rel. 22 CEU 
haplotypes (build 36) 
none 
R(GenABEL, 
ProABEL) 
EPIC Affymetrix 500K BRLMM call rate < 90%, pHWE < 10e-6 
                   
382,037  
IMPUTE 
0.3.1 
HapMap rel. 21 (Build 35) none 
SAS, Stata, Linux 
scripts 
Fenland Affymetrix 500K BRLMM 
call rate < 90%, pHWE < 10E-6, MAF < 
1% 
                   
362,055  
IMPUTE 
0.4.2 
HapMap rel. 22 (build 36) 
proper_inf
o<0.4 
Linux, Stata 10.1, 
SNPTEST 1.1.5 
FHS 
Affymetrix 500K  
Affymetrix 50K 
Affymetrix call rate < 95%, pHWE < 10E-6 
                   
503,526  
MACH 
1.0.15 
HapMap rel. 22 phased 
CEU haplotypes (build 36) 
none R 
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supplemental 
INCIPE Illumina Illumina call rate < 95%, pHWE < 10E-6 
                   
635,646  
IMPUTE 
0.2.0 
HapMap rel. 22 phased 
CEU haplotypes (build 36) 
none R 
KORA-F3 Affymetrix 500K BRLMM 
per-chip call rate < 93%, MAF < 
5%,discrepancy for one of the 50 
SNPs common on both chips, gender 
checks 
                   
380,407  
MACH HapMap rel. 22 (build 35) none 
MACH2QTL, 
ProbABEL, R, 
Visual Basic 
KORA-F4 Affymetrix 6.0 BRLMM 
per-chip call rate < 93%, per SNP call 
rate < 93%, MAF < 1%, gender checks 
                   
629,893  
MACH HapMap rel. 22 (build 36) none 
MACH2QTL, 
ProbABEL, R, 
Visual Basic 
LIFELINES 
Illumina 
CytoSNP12 v2 
GenomeStudio call rate < 95%, pHWE < 1E-05 
              
257,581   
HapMap rel. 22 phased 
CEU haplotypes (build 36) 
none NO 
MESA 
Affymetrix 
Genome-Wide 
Human SNP 
Array 6.0 
Birdseed v2 call rate < 95%, MAF ≤ 1% 
                   
897,979  
IMPUTE 
2.1.0 
HapMap rel. 22 phased 
CEU haplotypes (build 36) 
none PLINK 
MICROS 
Illumina Infinium 
HumanHap300 
v2 SNP bead 
microarrays 
Beadstudio 
call rate < 98%, pHWE < 10E-6, MAF < 
1% 
                   
292,917  
MACH 
1.0.16 
HapMap rel. 
22 (build 36) 
none 
R, GenABEL, 
ProbABEL; 
PREVEND 
Illumina 
CytoSNP12 v2 
GenomeStudio call rate < 95%, pHWE < 1E-05 
              
232,571   
HapMap rel. 22 phased 
CEU haplotypes (build 36) 
none NO 
SHIP Affymetrix 6.0 Birdseed2 none 
                   
869,224  
IMPUTE 
0.5.0 
HapMap rel. 
22 (build 36) 
none 
SNPTEST 1.1.5, 
QUICKTEST 0.94, 
R, InforSense, 
InterSystems 
Caché 
SHIP-TREND 
Illumina Human 
Omni 2.5 
GenomeStudio 
call rate ≤ 0.9, pHWE ≤ 1E-04, 
monomorphic SNPs 
               
1,782,967  
IMPUTE 
2.1.2.3 
HapMap rel. 22 phased 
CEU haplotypes (build 36) 
duplicate 
RSID but 
different 
positions 
QUICKTEST 0.95, 
R, InforSense, 
InterSystems 
Caché 
in silico replication  
GANI_MED 
Illumina Infinium 
PsychArray 
GenomeStudio 
call rate ≤ 0.95, pHWE ≤ 1E-04, MAF ≤ 
0.005 
               
305,145 
IMPUTE 
2.3.1 
1000 Genomes Phase I v3 
ALL (macGT1) (build 37) 
duplicate 
IDs (via 
positions) 
R, PLINK, gtool, 
InterSystems 
Caché 
GENDIAN 
Genome-Wide 
Human SNP 
Array 6.0  
Birdseed 
(BRLMM) 
n=126,259 SNPs (chr 1-chr22, chr X) 
were excluded from imputation by 
SNP QC due to one of the following: 
HWE-p < 10-6; monomorphic SNPs; 
MAF>.1 & call rate<.9 
MAF>.09 & MAF <=.1 & call rate<.91 
MAF>.08 & MAF <=.09 & call rate<.92 
            
747,402  
MACH 
1.0.18.c 
MiniMac 
2012-10-09 
GIANT ALL 1000G v3 ref 
panel GRCh (build 37) 
none R 
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MAF>.07 & MAF <=.08 & call rate<.93 
MAF>.06 & MAF <=.07 & call rate<.94 
MAF>.05 & MAF <=.06 & call rate<.95 
MAF>.04 & MAF <=.05 & call rate<.96 
MAF>.03 & MAF <=.04 & callr ate<.97 
MAF>.02 & MAF <=.03 & call rate<.98 
MAF>.01 & MAF <=.02 & call rate<.99 
MAF <=.01 & call rate<.99 
Vanderbilt 
Omni1 
Illumina 
HumanOmni1-
Quad 
BeadStudio 
call rate < 98%, IBD (Z0<0.8), Mendel 
errors > 0, Duplicate concordance < 
100% 
            
946,523  
IMPUTE 
2.3.0 
1000 Genomes Phase 1 
integrated v3 
Genotype 
Likelihood 
<0.9 
Plink and R 
Vanderbilt 
Omni5 
Illumina 
HumanOmni5-
Quad 
BeadStudio 
call rate < 98%, IBD (Z0<0.8), Mendel 
errors > 0, Duplicate concordance < 
100% 
         
3,819,154  
IMPUTE 
2.3.0 
1000 Genomes Phase 1 
integrated v3 
Genotype 
Likelihood 
<0.9 
Plink and R 
Vanderbilt 
660W 
Illumina 
Human660W-
Quad 
BeadStudio 
call rate < 98%, IBD (Z0<0.8), Mendel 
errors > 0, Duplicate concordance < 
100% 
            
530,014  
IMPUTE 
2.3.0 
1000 Genomes Phase 1 
integrated v3 
Genotype 
Likelihood 
<0.9 
Plink and R 
de novo replication  
  
genotyping 
platform 
amount of DNA 
used per SNP 
(in ng) genotyping method 
 n duplicates 
and 
concordanc
e per SNP 
(provide per 
individual 
SNP)  
number 
attempted
/number 
genotyped 
(per 
individual 
SNP) 
Other QC indices that 
your lab uses     
ESTHER 
LGC genomics 
SNP-line, using 
KASP Chemistry 
and 1536-well 
plates 
3.75 
De novo genotyping using KASPar 
v4.0 after whole 
genome amplification by primer 
extension preamplification (PEP) 
using thermostable DNA polymerases 
LGC 
Genomics 
does not 
add 
duplicates.  
The data for 
each SNP 
represents 
one reaction 
per sample.  
call rate 
range 0.98 
- 1 
none indicated by the lab 
 
  
SKIPOGH 
LGC genomics 
SNP-line, using 
KASP Chemistry 
and 1536-well 
plates 
5 -7.5 
De novo genotyping using KASPar 
v4.0 after whole 
genome amplification by primer 
extension preamplification (PEP) 
using thermostable DNA polymerases 
29 
participants 
were 
genotyped 
in duplicate. 
SNP 
concordance 
SNP call 
rates 
varied from 
94.5% to 
99.5% 
(median 
97.2) 
All assays have been 
validated on an in-house 
DNA panel (44 random 
Caucasian DNA samples). 
All sample plates 
genotyped include at least 
two negative controls. ie. 
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varied 
between 
86% and 
100%.  
blank/water controls. All 
genotyping data are 
initially generated by an 
automated algorithm 
(genotype calling based 
upon recorded 
fluorescence values). All 
genotyping data is 
manually checked and 
verified by no less than 
two experienced scientists 
at LGC genomics. 
KORAF4 non-
GWAS 
Mass ARRAY 
Analyzer 4 
system 
15 iPlex Gold 
At least 15% 
duplicate 
genotyping 
per SNP. 
Concordanc
e≥95%, 
median = 
100%  
NA NA 
 
  
KORAF3 non-
GWAS 
Mass ARRAY 
Analyzer 4 
system 
15 iPlex Gold 
At least 15% 
duplicate 
genotyping 
per SNP. 
Concordanc
e≥95%, 
median = 
100%  
NA NA 
 
  
SAPHIR 
Mass ARRAY 
Analyzer 4 
system 
15 iPlex Gold 
70 
duplicates; 
46 SNPs 
were 
genotyped; 
44 SNPs had 
a 
concordance 
of 100%; 2 
SNPs had 
each 1 
discordant 
sample   
46 SNPs 
were 
genotyped 
and had an 
aerage 
callrate of 
99,3% 
(between 
98.15% 
and 
99.65%) 
automatic calculation of 
the HWE, comparison of 
the obtained genotypes 
with HapMap Data 
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Supplementary Table 4: SNPs associated with UACR among all individuals with a p-value of <1E-05. 
 
SNPID chr 
position  
(hg18) Allele1 Allele2 
Fre-
quency 
Allele1 Effect SE p-value I
2 
% 
Sample 
Size In Gene Genes Within 100kb 
rs880315 1 10719453 t c 0.65 -0.042 0.009 9.1E-06 0 41333 CASZ1   
rs4072037 1 153428691 t c 0.54 0.029 0.006 2.5E-06 0 54450 MUC1 
MIR92B(dist=2901),THBS3(dist=3312),TRIM46(dist=4620),KRTCA
P2(dist=16263),MTX1(dist=16423),GBAP1(dist=21549),GBA(dist=
42172),DPM3(dist=49071),SLC50A1(dist=50733),EFNA1(dist=546
81),FAM189B(dist=54929),SCAMP3(dist=63703),CLK2(dist=70592
),HCN3(dist=85151),PKLR(dist=97017) 
rs914615 1 153442516 a g 0.47 -0.030 0.007 7.4E-06 0 44877 THBS3 
MTX1(dist=2598),GBAP1(dist=7724),MIR92B(dist=10829),MUC1(
dist=13186),TRIM46(dist=18445),GBA(dist=28347),KRTCAP2(dist=
30088),FAM189B(dist=41104),SCAMP3(dist=49878),CLK2(dist=56
767),DPM3(dist=62896),SLC50A1(dist=64558),EFNA1(dist=68506)
,HCN3(dist=71326),PKLR(dist=83192) 
rs17346504 2 137640231 t c 0.12 0.050 0.011 7.2E-06 27 53401 THSD7B   
rs9333289 2 187206352 t c 0.70 -0.030 0.007 9.3E-06 24 54441 ITGAV FAM171B(dist=60682) 
rs9333290 2 187227583 t g 0.30 0.038 0.008 7.5E-07 15 54441 ITGAV FAM171B(dist=39451) 
rs13006483 2 187230995 t g 0.30 0.037 0.008 1.2E-06 15 54441 ITGAV FAM171B(dist=36039) 
rs3816386 2 187236880 a g 0.69 -0.035 0.007 2.9E-06 0 54441 ITGAV FAM171B(dist=30154) 
rs11685758 2 187241613 t c 0.31 0.039 0.008 2.7E-06 0 44877 ITGAV FAM171B(dist=25421) 
rs12151442 2 187246092 t c 0.70 -0.030 0.007 5.5E-06 1 54441 ITGAV FAM171B(dist=20942) 
rs13001028 2 187255140 a g 0.69 -0.035 0.007 2.0E-06 0 54440 
 
ITGAV(dist=1266),FAM171B(dist=11894) 
rs13028817 2 187255744 t g 0.70 -0.029 0.007 7.3E-06 0 54439 
 
ITGAV(dist=1870),FAM171B(dist=11290) 
rs12615659 2 187259552 a t 0.30 0.030 0.007 4.3E-06 2 54439 
 
ITGAV(dist=5678),FAM171B(dist=7482) 
rs11678190 2 187268553 a c 0.69 -0.036 0.007 1.5E-06 0 54441 FAM171B ITGAV(dist=14679) 
rs17750683 2 187328542 a t 0.68 -0.033 0.007 4.1E-06 22 54439 FAM171B ZSWIM2(dist=71910),ITGAV(dist=74668) 
rs13026081 2 187334583 t c 0.32 0.032 0.007 6.8E-06 21 54434 FAM171B ZSWIM2(dist=65869),ITGAV(dist=80709) 
rs11783652 8 55021047 a g 0.32 0.037 0.008 2.4E-06 0 54450 RGS20 TCEA1(dist=20620) 
rs17301329 8 55021534 a t 0.29 0.042 0.008 5.6E-07 0 54450 RGS20 TCEA1(dist=20133),LYPLA1(dist=99946) 
rs16919699 8 55021582 t c 0.66 -0.037 0.008 2.3E-06 0 54450 RGS20 TCEA1(dist=20085),LYPLA1(dist=99898) 
rs1016013 9 96516305 a g 0.42 0.028 0.006 6.4E-06 5 54450 
 
C9orf3(dist=12467),FBP1(dist=73953),MIR2278(dist=95760) 
rs7851726 9 96543806 t c 0.42 0.027 0.006 5.2E-06 3 54450 C9orf3 MIR2278(dist=68259) 
rs446540 9 96549020 a g 0.43 0.028 0.006 5.8E-06 10 54304 C9orf3 MIR2278(dist=63045) 
rs183066 9 96557253 t c 0.57 -0.028 0.006 5.8E-06 9 54448 C9orf3 MIR2278(dist=54812) 
rs2584806 9 96569099 a c 0.58 -0.027 0.006 9.3E-06 9 54449 C9orf3 MIR2278(dist=42966) 
rs1109861 10 11286275 a c 0.55 -0.030 0.006 1.9E-06 5 54442 CELF2 CELF2-AS2(dist=98818) 
rs1801239 10 16959058 t c 0.90 -0.066 0.011 4.6E-09 31 54450 CUBN RSU1(dist=59599) 
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rs17343073 10 16972202 a t 0.90 -0.071 0.012 4.0E-09 22 54449 CUBN RSU1(dist=72743) 
rs6602163 10 17006772 a g 0.84 -0.056 0.009 1.2E-09 5 54450 CUBN   
rs10795433* 10 17009929 a c 0.86 -0.061 0.010 2.4E-10 6 54450 CUBN   
rs2417849 12 20167780 t c 0.37 0.028 0.006 9.5E-06 39 54441 
 
LOC100506393(dist=24711) 
rs2303658 12 20169697 a g 0.34 0.030 0.007 9.5E-06 31 54442 
 
LOC100506393(dist=26628) 
rs11609944 12 20170557 a g 0.38 0.028 0.006 9.6E-06 42 54449  LOC100506393(dist=27488) 
rs1728897 15 53088662 t c 0.54 -0.028 0.006 4.1E-06 0 54433 
 
  
rs12594729 15 53088684 a g 0.50 0.029 0.006 2.0E-06 0 54450 
 
  
rs7167661 15 53090751 t c 0.54 -0.028 0.006 3.5E-06 0 54450 
 
  
rs11071163 15 53091242 a g 0.50 -0.029 0.006 9.2E-06 0 54449 
 
  
rs7173577 15 53092295 a g 0.45 -0.029 0.006 2.3E-06 0 54450 
 
  
rs1728867 15 53094106 a g 0.45 -0.030 0.006 8.3E-07 0 54449 
 
  
rs951048 15 53094503 a t 0.44 -0.030 0.006 8.7E-07 0 54449 
 
  
rs2414396 15 53094680 a g 0.46 -0.031 0.006 7.6E-07 0 54449 
 
  
rs12907410 15 53095223 t c 0.56 0.028 0.006 3.7E-06 0 54449 
 
  
rs1728886 15 53095714 t c 0.56 0.030 0.006 1.2E-06 0 54449 
 
  
rs17818939 15 53096140 a g 0.44 -0.030 0.006 1.1E-06 0 54450 
 
  
rs1728878 15 53097144 t c 0.57 0.028 0.006 1.9E-06 0 54450 
 
  
rs8042768 15 53097375 a g 0.43 -0.028 0.006 2.1E-06 0 54448 
 
  
rs1690363 15 53098119 a g 0.43 -0.028 0.006 2.0E-06 0 54448 
 
  
rs1690365 15 53098549 t c 0.56 0.028 0.006 1.9E-06 0 54450 
 
  
rs1614271 15 53098677 t c 0.57 0.029 0.006 1.6E-06 0 54448 
 
  
rs1690366 15 53098855 t g 0.44 -0.030 0.006 2.0E-06 0 54448 
 
  
rs1690367 15 53099066 a g 0.43 -0.028 0.006 1.8E-06 0 54406 
 
  
rs7180127 15 53103432 t c 0.51 0.029 0.006 3.7E-06 0 54449 
 
  
rs10083619 15 53106962 a g 0.51 0.029 0.006 3.5E-06 0 54448 
 
  
rs2899576 15 53107909 t c 0.48 -0.030 0.006 1.2E-06 0 54424 
 
  
rs1528472 15 53108420 a c 0.48 -0.032 0.006 5.4E-07 0 54445 
 
  
rs17238122 15 53109188 a g 0.48 -0.031 0.006 8.8E-07 0 54443 
 
  
rs1528477 15 53111680 a g 0.48 -0.031 0.006 1.5E-06 0 54449 
 
  
rs1830324 15 53112207 a g 0.51 -0.030 0.006 3.4E-06 0 54449 
 
  
rs11858741 15 53112699 a g 0.51 0.030 0.006 2.2E-06 0 54450    
rs231226 19 40959617 t c 0.62 -0.033 0.007 5.1E-06 22 44877 ARHGAP33 
PROSER3(dist=7700),LINC01529(dist=12001),HSPB6(dist=19847),
LIN37(dist=22357),PRODH2(dist=23115),PSENEN(dist=29721),U2
AF1L4(dist=31434),IGFLR1(dist=34426),KMT2B(dist=37996),NPHS
1(dist=48497),ZBTB32(dist=59837),KIRREL2(dist=80033),APLP1(di
st=91624),UPK1A(dist=98390) 
rs231227 19 40959907 a g 0.38 0.033 0.007 4.9E-06 22 44877 ARHGAP33 
PROSER3(dist=7990),LINC01529(dist=11711),HSPB6(dist=20137),
LIN37(dist=22647),PRODH2(dist=22825),PSENEN(dist=30011),U2
AF1L4(dist=31724),IGFLR1(dist=34716),KMT2B(dist=38286),NPHS
1(dist=48207),ZBTB32(dist=60127),KIRREL2(dist=79743),APLP1(di
st=91334),UPK1A(dist=98680) 
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rs2828785 21 24359376 t c 0.27 -0.038 0.008 7.9E-06 0 54450     
             Standard error (SE) and p-values are corrected for genomic control. A1 is the coded allele. 
*The previously identified missense variant rs18012399 in CUBN is correlated with the index variant rs10795433 in this study (r
2
=0.54 and D’=1, based on HapMap r22 CEU data) 
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Supplementary Table 5: SNPs associated with MA among all individuals with a p-value of <1E-05. 
 
SNPID chr 
position  
(hg18) 
Allele
1 
Allele
2 
Fre-
quency 
Allele1 Effect SE p-value I
2 
% 
Sample 
Size In Gene Genes Within 100kb 
rs11579312 1 30429159 t c 0.69 0.11 0.025 9.7E-06 0 54116     
rs3795324 1 158909735 a c 0.82 -0.15 0.031 9.4E-07 22 52716   
CD48(dist=5425),SLAMF1(dist=26010),SLAMF7(dist=65736),CD
84(dist=93805) 
rs16827742 2 150615405 a g 0.06 0.30 0.063 3.1E-06 12 35962     
rs9333289 2 187206352 t c 0.71 -0.10 0.022 5.2E-06 0 54107 ITGAV FAM171B(dist=60682) 
rs9333290 2 187227583 t g 0.29 0.11 0.023 5.0E-06 0 54107 ITGAV FAM171B(dist=39451) 
rs13006483 2 187230995 t g 0.29 0.10 0.023 7.0E-06 0 54107 ITGAV FAM171B(dist=36039) 
rs12151442 2 187246092 t c 0.70 -0.10 0.022 2.0E-06 0 54107 ITGAV FAM171B(dist=20942) 
rs13001028 2 187255140 a g 0.70 -0.10 0.023 8.3E-06 0 54106 
 
ITGAV(dist=1266),FAM171B(dist=11894) 
rs13028817 2 187255744 t g 0.70 -0.10 0.022 2.1E-06 0 54105 
 
ITGAV(dist=1870),FAM171B(dist=11290) 
rs12615659 2 187259552 a t 0.30 0.11 0.022 1.3E-06 0 54105 
 
ITGAV(dist=5678),FAM171B(dist=7482) 
rs11678190 2 187268553 a c 0.70 -0.10 0.023 5.1E-06 0 54107 FAM171B ITGAV(dist=14679) 
rs17750683 2 187328542 a t 0.68 -0.11 0.022 1.4E-06 0 54105 FAM171B ZSWIM2(dist=71910),ITGAV(dist=74668) 
rs13026081 2 187334583 t c 0.32 0.11 0.022 1.6E-06 0 54093 FAM171B ZSWIM2(dist=65869),ITGAV(dist=80709) 
rs1077216 3 46867165 t c 0.07 0.20 0.044 5.2E-06 5 45096   
MYL3(dist=7196),PRSS42(dist=16576),PTH1R(dist=27075),CCDC
12(dist=71059) 
rs13160548 5 38814607 t c 0.69 -0.10 0.023 8.2E-06 14 53130 OSMR-AS1 LINC01265(dist=58475),OSMR(dist=67110) 
rs12719264 5 119211839 a g 0.30 -0.11 0.025 6.2E-06 29 54115     
rs2110904 6 107701464 t c 0.65 0.10 0.022 8.9E-06 0 54116 PDSS2   
rs538641 8 103072879 a g 0.05 0.28 0.062 7.8E-06 0 50048 NCALD   
rs1801239 10 16959058 t c 0.90 -0.23 0.035 1.7E-10 18 54115 CUBN RSU1(dist=59599) 
rs17343073 10 16972202 a t 0.90 -0.23 0.036 3.0E-10 0 54115 CUBN RSU1(dist=72743) 
rs6602163 10 17006772 a g 0.83 -0.17 0.029 1.5E-09 5 54116 CUBN   
rs10795433 10 17009929 a c 0.85 -0.20 0.031 1.3E-10 4 54116 CUBN   
rs12764441 10 72361657 t c 0.48 -0.10 0.021 3.5E-06 0 54116   PCBD1(dist=43108),SGPL1(dist=50719) 
rs3740393 10 104626645 c g 0.21 0.13 0.028 6.1E-06 19 54048 
C10orf32-
ASMT 
C10orf32(dist=11937),CYP17A1(dist=39365),CNNM2(dist=4142
0),WBP1L(dist=60634) 
rs10899033 11 74070819 c g 0.72 0.11 0.025 9.3E-06 0 54116   
CHRDL2(dist=14303),MIR4696(dist=38142),POLD3(dist=39066),
RNF169(dist=66742) 
rs10498273 14 20214639 c g 0.94 -0.21 0.047 9.6E-06 36 53131   
ANG(dist=7537),RNASE4(dist=7573),OR6S1(dist=34949),EDDM3
A(dist=69300),LOC254028(dist=69419),RNASE12(dist=85817),R
NASE11(dist=86382),EDDM3B(dist=91787) 
rs7145202 14 22161945 t c 0.62 0.10 0.022 3.7E-06 0 54106 
 
ABHD4(dist=10840),DAD1(dist=33962) 
rs6572602 14 22163380 a g 0.62 0.11 0.024 4.6E-06 0 41412  ABHD4(dist=12275),DAD1(dist=35397) 
rs274173 19 61384255 c g 0.17 -0.23 0.051 5.2E-06 12 38796 GALP 
ZSCAN5B(dist=8615),ZNF444(dist=20181),ZSCAN5A(dist=40236)
,ZNF787(dist=59701) 
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rs6030216 20 40486448 t c 0.17 0.12 0.027 6.0E-06 0 54115 PTPRT   
rs4812598 20 40487956 c g 0.83 -0.12 0.027 9.1E-06 0 54115 PTPRT   
rs6513791 20 40491536 t c 0.18 0.12 0.026 4.4E-06 12 54115 PTPRT   
rs4810356 20 40491604 t c 0.82 -0.13 0.028 7.6E-06 11 54115 PTPRT   
rs6030232 20 40496297 a t 0.82 -0.12 0.027 8.7E-06 0 54115 PTPRT   
rs6030238 20 40498930 a g 0.81 -0.12 0.026 6.0E-06 12 54115 PTPRT   
 
Odds rations can be obtained by exponentiating the effect to the basis e. 
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Supplementary Table 6: SNPs associated with UACR among individuals without diabetes with a p-value of <1E-05. 
 
SNPID chr 
position  
(hg18) 
Allele
1 
Allele
2 
Fre-
quency 
Allele1 Effect SE p-value I
2 
% 
Sample 
Size In Gene Genes Within 100kb 
rs17377079 1 84999401 a g 0.15 0.060 0.013 6.9E-06 9 46061   LPAR3(dist=52273),SSX2IP(dist=70573) 
rs4072037 1 153428691 t c 0.54 0.028 0.006 8.5E-06 0 46061 MUC1 
MIR92B(dist=2901),THBS3(dist=3312),TRIM46(dist=4620),KRTC
AP2(dist=16263),MTX1(dist=16423),GBAP1(dist=21549),GBA(di
st=42172),DPM3(dist=49071),SLC50A1(dist=50733),EFNA1(dist
=54681),FAM189B(dist=54929),SCAMP3(dist=63703),CLK2(dist
=70592),HCN3(dist=85151),PKLR(dist=97017) 
rs9333290 2 187227583 t g 0.30 0.037 0.008 4.1E-06 3 46052 ITGAV FAM171B(dist=39451) 
rs13006483 2 187230995 t g 0.30 0.035 0.008 6.7E-06 3 46052 ITGAV FAM171B(dist=36039) 
rs13001028 2 187255140 a g 0.69 -0.034 0.008 9.9E-06 0 46052 
 
ITGAV(dist=1266),FAM171B(dist=11894) 
rs11678190 2 187268553 a c 0.69 -0.035 0.008 8.7E-06 0 46052 FAM171B ITGAV(dist=14679) 
rs17750683 2 187328542 a t 0.68 -0.035 0.008 4.6E-06 0 46052 FAM171B ZSWIM2(dist=71910),ITGAV(dist=74668) 
rs13026081 2 187334583 t c 0.32 0.034 0.008 8.3E-06 0 46045 FAM171B ZSWIM2(dist=65869),ITGAV(dist=80709) 
rs4674086 2 201032130 t c 0.46 0.028 0.006 8.7E-06 0 45053 SPATS2L KCTD18(dist=29799),SGOL2(dist=66980) 
rs9372871 6 127849645 t c 0.89 -0.046 0.010 4.2E-06 2 45094 SOGA3 KIAA0408(dist=27417),C6orf58(dist=90367) 
rs9372872 6 127849848 c g 0.11 0.046 0.010 2.5E-06 0 46061 SOGA3 KIAA0408(dist=27620),C6orf58(dist=90164) 
rs7739650 6 127850605 a g 0.11 0.046 0.010 3.1E-06 2 46061 SOGA3 KIAA0408(dist=28377),C6orf58(dist=89407) 
rs13220247 6 127850652 t c 0.89 -0.046 0.010 3.4E-06 2 46061 SOGA3 KIAA0408(dist=28424),C6orf58(dist=89360) 
rs9388580 6 127851073 t c 0.89 -0.044 0.010 8.7E-06 6 46061 SOGA3 KIAA0408(dist=28845),C6orf58(dist=88939) 
rs12668467 7 13598753 t c 0.27 -0.043 0.009 4.1E-06 0 46061     
rs1801239 10 16959058 t c 0.90 -0.054 0.012 4.4E-06 25 46061 CUBN RSU1(dist=59599) 
rs10795433 10 17009929 a c 0.86 -0.045 0.010 8.7E-06 14 46061 CUBN   
rs2192224 15 24959369 t g 0.13 0.048 0.011 6.1E-06 0 46061 GABRG3 LOC101928869(dist=26259) 
rs7173577 15 53092295 a g 0.45 -0.029 0.006 6.7E-06 0 46061 
 
  
rs1728867 15 53094106 a g 0.45 -0.028 0.006 7.4E-06 0 46061 
 
  
rs951048 15 53094503 a t 0.44 -0.028 0.006 7.8E-06 0 46061 
 
  
rs2414396 15 53094680 a g 0.46 -0.029 0.006 4.1E-06 0 46061 
 
  
rs17818939 15 53096140 a g 0.44 -0.028 0.006 9.9E-06 0 46061 
 
  
rs2899576 15 53107909 t c 0.48 -0.029 0.006 5.7E-06 0 46035 
 
  
rs1528472 15 53108420 a c 0.48 -0.030 0.007 3.1E-06 0 46056 
 
  
rs17238122 15 53109188 a g 0.48 -0.030 0.007 4.8E-06 0 46054 
 
  
rs1528477 15 53111680 a g 0.48 -0.030 0.007 6.6E-06 0 46061 
 
  
rs11858741 15 53112699 a g 0.51 0.029 0.007 7.9E-06 0 46061    
rs4528660 18 3033516 t c 0.91 -0.073 0.017 9.4E-06 3 33478   
MYOM1(dist=23289),LPIN2(dist=31571),LOC727896 
(dist=96895) 
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Supplementary Table 7: SNPs associated with UACR among individuals with diabetes with a p-value of <1E-05. 
 
SNPID chr 
position  
(hg18) 
Allele
1 
Allele
2 
Fre-
quency 
Allele1 Effect SE p-value I
2 
% 
Sample 
Size In Gene 
Genes Within 100kb 
[Closest Gene] 
rs13427836 2 128744431 t c 0.14 0.199 0.044 6.1E-06 10 5509 HS6ST1 UGGT1(dist=74712) 
rs13428208 2 128744772 t c 0.14 0.195 0.044 7.6E-06 10 5509 HS6ST1 UGGT1(dist=75053) 
rs2405747 2 128748295 t c 0.15 0.193 0.043 6.9E-06 14 5509 HS6ST1 UGGT1(dist=78576) 
rs4662787 2 128752447 t c 0.18 0.176 0.040 9.0E-06 0 5824 HS6ST1 UGGT1(dist=82728) 
rs10183821 2 128753139 a g 0.81 -0.169 0.038 9.3E-06 0 5825 HS6ST1 UGGT1(dist=83420) 
rs13079877 3 2102845 a g 0.45 0.148 0.033 5.6E-06 25 5825   CNTN4(dist=12705),CNTN4-AS2(dist=24248) 
rs7634770 3 67012918 a c 0.70 -0.142 0.030 2.7E-06 19 5825 
 
[KBTBD8, dist=119174] 
rs9876318 3 67014118 a t 0.69 -0.144 0.030 2.0E-06 20 5824  [KBTBD8, dist=117974] 
rs17738155 6 51264035 t c 0.92 -0.241 0.053 5.9E-06 39 5825 
 
[PKHD1, dist=324068] 
rs947724 6 51274689 t c 0.92 -0.239 0.053 7.5E-06 41 5825  [PKHD1, dist=313414] 
rs7792461 7 29479920 t g 0.39 0.130 0.029 5.1E-06 0 5825 CHN2 PRR15(dist=90032) 
rs4722909 7 29481456 a g 0.60 -0.134 0.029 3.2E-06 0 5823 CHN2 PRR15(dist=88496) 
rs4722913 7 29482735 a g 0.61 -0.131 0.029 4.2E-06 0 5825 CHN2 PRR15(dist=87217) 
rs7798161 7 29483162 a g 0.61 -0.130 0.029 4.7E-06 0 5825 CHN2 PRR15(dist=86790) 
rs3828977 7 29486023 a g 0.59 -0.131 0.029 4.9E-06 0 5825 CHN2 PRR15(dist=83929) 
rs7922045 10 122991722 t c 0.26 0.165 0.033 5.7E-07 0 5824 
 
[FGFR2, dist=236111] 
rs729014 10 122992796 t c 0.15 0.202 0.043 2.4E-06 0 5825  [FGFR2, dist=235037] 
rs649529 11 87647899 t g 0.43 -0.147 0.033 9.3E-06 0 5825   CTSC(dist=18509),RAB38(dist=99616) 
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Supplementary Table 8: Discovery, replication and combined estimates for all index SNPs associated with UACR in diabetes in the 
discovery sample at p<1E-05 
 
            discovery  replication combined 
Marker 
gene 
nearby chr 
position 
(hg18) 
A
1 
A 
2 
Freq 
A1 beta SE p-value I
2 
% n 
Freq 
A1 beta SE p-value I
2 
% n 
Freq 
A1 beta SE p-value I
2 
% n 
rs13427836 HS6ST1 2 128744431 t c 0.14 0.20 0.04 6.1E-06 10 5509 0.15 0.16 0.07 3.13E-02 58 1890 0.15 0.19 0.04 6.31E-07 30 7399 
rs13079877 CNTN4 3 2102845 a g 0.45 0.15 0.03 5.6E-06 25 5825 0.50 0.04 0.05 5.16E-01 0 1880 0.46 0.12 0.03 2.40E-05 20 7705 
rs9876318 KBTBD8 3 67014118 a t 0.69 -0.14 0.03 2.0E-06 20 5824 0.69 0.08 0.06 1.56E-01 0 1897 0.69 -0.09 0.03 4.86E-04 37 7721 
rs17738155 PKHD1 6 51264035 t c 0.92 -0.24 0.05 5.9E-06 39 5825 0.92 0.06 0.10 5.30E-01 0 1896 0.92 -0.17 0.05 2.51E-04 42 7721 
rs4722909 CHN2 7 29481456 a g 0.60 -0.13 0.03 3.2E-06 0 5823 0.60 0.09 0.05 9.66E-02 40 1894 0.60 -0.08 0.03 9.92E-04 38 7717 
rs7922045 FGFR2 10 122991722 t c 0.26 0.17 0.03 5.7E-07 0 5824 0.23 -0.10 0.06 1.05E-01 35 1824 0.25 0.11 0.03 2.41E-04 39 7648 
rs649529 RAB38 11 87647899 t g 0.43 -0.15 0.03 9.3E-06 0 5825 0.43 -0.12 0.05 1.91E-02 0 1962 0.43 -0.14 0.03 5.84E-07 0 7787 
A1 is the coded allele (effect allele), i.e. the beta corresponds to the effect by which UACR changes per each additional copy of the coded allele. 
The I
2
 statistic of the combined results was obtained from a separate analysis incorporating each discovery file with single GC-correction and the replication files. Standard error (SE) 
and p-value of the combined results are based on double-GC corrected results as described in the methods. 
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Supplementary Table 9: Association results for the index SNPs near RAB38/CTSC and in HS6ST1 in the DCCT/EDIC Study 
 
incident microalbuminuria (1244 individuals [268 cases]; primary endpoint)  
SNP effect alelle frequency of 
effect allele 
effect se p-value 
rs649529 T 0.42 0.04 0.09 0.64 
rs13427836 T 0.14 -0.18 0.14 0.20 
      
time to macroalbuminuria or ESRD (1304 individuals [133 cases]; secondary endpoint) 
SNP effect alelle frequency of 
effect allele 
effect se p-value 
rs649529 T 0.42 0.24 0.14 0.09 
rs13427836 T 0.14 -0.31 0.22 0.16 
 
Cox proportional hazards regression models were used to estimate hazard ratios after adjustment for cohort status (primary vs. 
secondary), treatment (intensive vs. conventional), cohort*treatment interaction (stratified by DCCT year of entry), age of diagnosis 
squared, sex, diabetes duration squared, body mass index, blood pressure, triglyceride, HDL-C, total cholesterol, smoking (all at 
baseline), as well as time-dependent updated mean A1C, and time-dependent indicators for hypertension diagnosis and treatment. 
Imputation quality (rs13427836) and call rate (rs649529) were both >=0.99. 
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